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 7 
ABSTRACT 
 
Campylobacter jejuni and C. coli are the leading causes of human bacterial gastroenteritis 
in developed countries. In Finland, since 1998, the number of reported cases of 
Campylobacter infection has exceeded that of Salmonella. In the year 2008 there were 4453 
reported cases of Campylobacter. Most human Campylobacter infections are sporadic and a 
seasonal peak in the distribution of infections can be seen in the summer months in several 
countries, including Finland.  A variety of risk factors for Campylobacter infections have 
been identified; handling and eating poultry, drinking unpasteurized milk, contact with 
domestic animals, and travelling abroad. However, the relative importance of the different 
risk factors in sporadic cases of Campylobacter infection remains unknown. In most cases, 
the infection is self-limiting and no specific treatment is required. Campylobacter enteritis 
can cause a wide range of complications, including reactive arthritis (ReA) that is reported 
in 1-5% of the cases. 
 
Seven clinical microbiology laboratories serving different geographical areas of Finland, 
participated in this multi-center study, conducted during a seasonal peak in 2002. In a 
matched case-control study, domestically-acquired sporadic Campylobacter infections from 
three geographical areas were collected. The final study comprised 100 cases and 137 
controls.  Risk factors for sporadic domestically-acquired Campylobacter infections were 
identified on the basis of a questionnaire; swimming in natural waters was found to be a 
novel risk factor for Campylobacter infection. Other independent risk factors were tasting 
or eating raw or undercooked meat and drinking untreated water from a dug well. 
 
The role of bacterial strain and host characteristics are not fully understood in 
Campylobacter infections. Exposure factors, demographical characteristics, and the 
serotype  of  the  Campylobacter isolate  may affect  the  severity  of  the  enteritis.  This  cross-
sectional study comprised 114 patients with C. jejuni enteritis, diagnosed in three clinical 
microbiology laboratories; most of the patients had participated in the previous case-control 
study. Swimming was associated with age ? 5 years and serotype Pen 6,7 was found 
significantly more often among patients reporting swimming. The geographical distribution 
among serotypes varied; serotype Pen 4-complex appeared more often in patients from 
urban areas and serotype Pen 21 among patients from more rural areas. Thus, risk factors 
and sources of infection for C. jejuni infection may vary among individuals depending on 
age and geographical location.  
 
The in vitro susceptibilities of C. jejuni and C. coli strains isolated from patients infected 
abroad (85 strains) or domestically (393 strains) revealed that susceptibility to 
erythromycin is still high, even among isolates of foreign origin. However, the novel 
antimicrobial agent telithromycin did not offer any advantage over erythromycin; isolates 
with high minimal inhibitory concentrations (MICs) for erythromycin also showed reduced 
susceptibility to telithromycin. Reduced susceptibility to fluoroquinolones was detected 
almost exclusively among isolates of foreign origin and half of these isolates with high 
MICs for fluoroquinolones also showed elevated MICs for doxycycline. 
 
 8 
Questionnaires concerning complications associated with C. jejuni enteritis  were  sent  to  
patients two months after becoming ill; 201 patients from seven different geographical 
areas were included in the study. Musculoskeletal complications after C. jejuni infection 
were  commonly  reported  by  patients  (39%).  The  incidence  of  classical  ReA was  4% and 
that of Achilles enthesopathy and/or heel pain 9%. Other C. jejuni-associated reactive joint 
symptoms were commonly reported, however, due to their milder nature seldom seen and 
diagnosed by a physician. The severity of the enteritis may predict further complications; 
stomach ache during enteritis was connected to the development of later joint pain. Early 
antimicrobial treatment, within two days from the start of symptoms, shortened the duration 
of diarrhoea by two days but did not prevent later musculoskeletal complications. 
 
Campylobacter is an important human enteropathogen and causes a significant burden of 
illness. As the incidence of Campylobacter infections is high, the relative importance of the 
infection and the occurrence of complications will increase. This stresses the importance of 
understanding the risk factors for acquiring Campylobacter infection and how the 
characteristics of the host and bacterial strain may affect the risk for infection. The role of 
antimicrobial treatment for acute Campylobacter enteritis seems to be marginal and should 
be used restrictively. 
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1. INTRODUCTION 
 
Campylobacter species was first associated with human enteric illness in 1972 (Dekayser et 
al., 1972; Butzler et al., 1973; Skirrow & Butzler, 2000) and the real breakthrough came 
when Skirrow developed a selective growth media (Skirrow, 1977) enabling a simpler 
isolation method for Campylobacter. In the mid-1980’s Campylobacter was recognized as 
the most frequent cause of bacterial enteritis in humans in developed countries (Blaser, 
1997; Rautelin & Hänninen, 2000) and in 1998, in Finland, the number of reported cases of 
Campylobacter exceeded that of Salmonella for the first time (Rautelin & Hänninen, 2000).  
In Finland, in the years 2000 to 2008, the number of reported cases has varied between 
3178 to 4453, with C. jejuni being  the  most  prevalent  covering  almost  80%  (www.ktl.fi, 
accessed March 2009).  
 
The majority of human Campylobacter infections are sporadic and a seasonal peak in 
Campylobacter infections during the summertime has been observed in many countries 
including Finland (Rautelin & Hänninen, 2000; Nylen et al., 2002; Kovats et al., 2005). 
Several studies have identified a variety of risk factors including handling and eating 
poultry meat (Kapperud et al., 1992; Eberhart-Phillips et al., 1997; Studahl & Andersson, 
2000; Neimann et al., 2003), drinking unpasteurized milk (Schmid et al., 1987; Eberhart-
Phillips et al., 1997; Studahl & Andersson, 2000; Neimann et al., 2003) handling domestic 
animals (Kapperud et al., 1992; Eberhart-Phillips et al., 1997; Studahl & Andersson, 2000; 
Neimann et al., 2003), and travelling abroad (Eberhart-Phillips et al., 1997; Neimann et al., 
2003). There is, however, still considerable uncertainty as to the relative importance of 
these risk factors in sporadic cases. 
  
The role of bacterial strain and host characteristics in the acquisition of Campylobacter 
infection is not known. Factors that may influence the outcome of Campylobacter infection, 
such as length of disease, hospitalization, or antimicrobial treatment, have not been 
clarified. Certain serotypes have been shown to be associated with some complications; 
heat-stable (HS) serotype 19 with Guillain-Barré syndrome (GBS) (Kuroki et al., 1993) and 
HS serotype 2 with Miller-Fisher syndrome (MFS) (Neisser et al.,  1997).  The severity of 
the acute diarrheal disease, however, has not been linked to any specific serotype. 
 
Campylobacter enteritis is usually a self-limiting disease not requiring specific treatment, 
and antimicrobial therapy is usually reserved for complicated disease only (Blaser & 
Engberg, 2008).  However, some studies have shown that antimicrobial therapy may 
shorten the duration of the enteritis (Mattila et al., 1993; Ternhag et al., 2007) and there is 
evidence of frequent antimicrobial therapy (Feodoroff et al., 2009; Townes et al., 2008). 
Macrolides are the drugs of choice whereas resistance to fluoroquinolones was already high 
15 years ago (Rautelin et al., 1991; Endtz et al., 1991; Smith et al., 1999; Engberg et al., 
2001). 
 
Campylobacter enteritis can cause a wide range of complications. Reactive arthritis (ReA) 
is reported in about 1-5% of Campylobacter cases (Pope et al., 2007) but even up to 7% has 
been reported (Hannu et al., 2002). Other reactive musculoskeletal symptoms, such as 
enthesopathy are common (Hannu et al., 2002; Townes et  al., 2008). Another important, 
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although rare, Campylobacter enteritis-related complication is GBS (Tam et al., 2006); C. 
jejuni is considered the predominant preceding infection for this condition of acute 
neuromuscular paralysis (Jacobs et al., 2008). 
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2. REVIEW OF THE LITERATURE 
 
 
2.1 Historical aspects 
 
In 1886 Escherich described a spiral bacterium found in the stool and colon of infants who 
had died from “cholera infantum”. It was not however, until 1986 that Kist reported this 
finding, which probably is the first description of Campylobacter spp. (Kist, 1986). The 
genus Campylobacter was first proposed by Sebald and Véron in 1963 (Sebald &Véron, 
1963) and is Greek for curved rod. The breakthrough came when Dekeyser and Butzler 
(Dekeyser et al., 1972; Butzler et al., 1973) isolated ‘related vibrio’ from human blood and 
stool samples using a special filtration technique. Thereafter, Skirrow developed a simpler 
technique and a selective medium for culturing C. jejuni and C. coli from stool samples 
(Skirrow, 1977).  Interestingly, this bacterium had been known to veterinarians for half a 
century causing abortions in cattle and sheep (McFadyean & Stockman, 1913; Smith, 1919; 
Smith & Taylor, 1919). In 1973 Verón and Chatelain (Véron & Chatelain, 1973) identified 
four species within the genus Campylobacter; C. jejuni, C. coli, C. fetus, and C. sputorum.  
  
                                                                                                                                                              
2.2 Campylobacter spp. 
 
2.2.1 General description 
 
The genera Campylobacter and Arcobacter belong to the Campylobacteraceae family 
(Vandamme & De Ley, 1991) which belongs to the class of ?-proteobacteria (Trust et al., 
1994) together with Helicobacter and Wolinella.  Twelve of the 18 species comprising the 
genus Campylobacter have been identified as human pathogens. C. jejuni and C. coli are by 
far the most important human enteropathogens among the campylobacters.  Other less 
common human enteropathogens include C. upsaliensis (Lindblom et al., 1995) and C. lari 
(Broczyk, 1987; Lastovica & Allos, 2009). Together with C. lari and C. upsaliensis, C. 
jejuni and C. coli form a group of thermophilic enteropathogens, which typically grow at a 
high temperature (42 °C). C. fetus infection usually occurs in compromised elderly patients, 
with chronic underlying disease or an immunosuppressive state, causing bacteraemia 
sometimes with a fatal outcome (Skirrow et al., 1993; Gazaigne et al., 2008; Pacanowski et 
al., 2008). Diarrhoeal illness caused by C. fetus has also been described (Rennie et al., 
1994; Lastovica & Allos, 2008). Other Campylobacter species such as C. hyointestinalis 
(Edmonds, 1987), C. sputorum (Lindblom et al., 1995; Lastovica & Allos, 2008), C. curvus 
(Abbot et al., 2005), and C. concisus (Lindblom et al., 1995; Debruyne et al., 2008) have 
been isolated from human stools, but their role as enteropathogens is to be determined. 
 
To date the complete genomes of nine Campylobacter strains have been identified, of 
which three are C. jejuni spp. jejuni (http://cmr.jcvi.org/cgibin/CMR/shared/Genomes.cgi) 
(Accessed January 2009) 
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2.2.2 Species identification 
 
Campylobacters are S-shaped or spirally curved rods that are 0.2 to 0.9?m wide and 0.5 to 
5 ?m long (Fitzgerald & Nachamkin, 2007). Most campylobacters are motile, owing to a 
single polar unsheathed flagellum at one or both ends of the bacterium (Fitzgerald & 
Nachamkin, 2007). Campylobacter species are Gram-negative and in general oxidase-
positive. They may form spherical or coccoid bodies if exposed to air for prolonged 
periods; this is a degenerated form that has lost its motility and is difficult to subculture 
(Buck et al., 1983).  A microaerobic atmosphere containing nitrogen (85%), carbon dioxide 
(10%), and oxygen (5%) is required for optimal recovery of most Campylobacter species. 
Some phenotypic characteristics of the most important human enteropathogens, including 
C. fetus, are shown in Table 1.  
 
Table 1. Phenotypic characteristics of human Campylobacter enteropathogens (adopted from Lastovica & 
Allos, 2008)* 
 
Species Oxidase Catalase Hippurate 
hydrolysis 
Growth at 
25°C 
Growth at 
42°C 
C. jejuni 
C. coli 
C.upsaliensis 
C. lari 
C. fetus** 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
(+) 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
(-) 
+ 
+ 
+ 
(+) 
+ 
(-) 
*+, positive; (+), most strains positive; -, negative; (-), most strains negative 
**Primarily causes bacteraemia, but has been described to cause diarrhoeal illness 
 
 
2.2.3 Serotyping methods 
 
There are two Campylobacter serotyping methods for C. jejuni and C. coli; the Penner 
scheme (Penner & Hennessey, 1980) based on heat-stable (HS) antigens and the Lior 
scheme (Lior et al., 1982) based on the identification of heat-labile (HL) antigens. The 
major serodeterminant of the HS system is a capsular polysaccharide and the 
serodeterminants of the HL system include uncharacterized bacterial surface antigens and 
in some serotypes flagellar antigens (Fitzgerald et al., 2008). The complete serotyping 
scheme is mainly performed at reference laboratories, yet a commercial set of antisera is 
available for assigning isolates to a limited number of different serotypes. The Penner 
system can identify over 60 different serotypes for C. jejuni and C. coli, while the originally 
described method by Lior and colleagues (Lior et al., 1982)  detects over 100 serotypes for 
C. jejuni, C. coli, and C. lari (Fitzgerald et al., 2008). The major disadvantage of these two 
serotyping methods is the high number of untypeable strains and the restricted reagent 
availability.  
 
2.2.4  Other typing methods 
 
Other methods developed for subtyping C. jejuni and C. coli isolates include biotyping 
(Lior, 1984) and phage typing (Khakhria & Lior, 1992). Phage typing has been used as an 
extension to serotyping for more detailed characterization by subdividing the predominant 
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serotypes into phage types (Frost et al., 1999). All of the three published Campylobacter 
phage typing schemes (Grajewski et al., 1985; Salama et al., 1990; Khakhria & Lior, 1992) 
are closely related and have some common phages. Biotyping, which relies on phenotypic 
differences between species, has only been used to a limited extent. 
 
Several methods for genotyping Campylobacter have been developed. Advantages of 
genotyping techniques include the low number of untypeable strains and the potential to 
become universally available. The most commonly used genotyping methods for subtyping 
Campylobacter are pulse-field gel electrophoresis (PFGE), amplified fragment length 
polymorphism (AFLP), ribotyping, fla typing, and multilocus sequence typing (MLST) 
(Wassenaar & Newell, 2000).  
 
 
2.3 Epidemiology of Campylobacter jejuni/coli infections 
 
2.3.1 General aspects 
 
Campylobacter species are primarily zoonotic, with a variety of animals implicated as 
reservoirs of human infection (Table 2). In 2007, Campylobacter infections were the most 
frequently reported zoonotic disease in humans across the European Union with 200 507 
cases compared to 175 561 in the previous year (EFSA, 2009). The most prevalent species 
(of those specified) are C. jejuni (accounting for 90 to 95% of infections) and C. coli 
(accounting for 5 to 10% of infections).  
 
 
Table 2. Reservoirs of C. jejuni and C. coli species (adopted from Fitzgerald & Nachamkin, 2007) 
 
Species 
 
Cattle Pigs Wild 
birds 
Poultry Pets 
C. jejuni  
C. coli 
    x 
 
 
 
   x 
     x 
     x 
 
     x 
     x 
 
    x 
 
 
 
 
In Finland, since 1994 all clinical microbiology laboratories have been required to report 
Campylobacter infections to the National Infectious Disease Register (NIDR). Since 1998, 
the number of reported Campylobacter infections has exceeded that of Salmonella 
(www.ktl.fi) (Figure 1).  
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Figure 1. Number of reported Campylobacter and Salmonella cases in Finland from 1997 to 2008 according 
to NIDR 
 
However, the true rate of campylobacteriosis is thought to be considerably higher than the 
number of reported cases as many patients never see a physician, not all patients visiting a 
physician are sampled, and not all positive cases are reported (Wheeler et al., 1999; EFSA, 
2005). The number of laboratory-confirmed infections has been suggested to be up to a 20-
fold underestimation of the true incidence due to under-reporting (Mazick et al., 2006). 
 
In Finland, there were slightly more male cases (51.4% to 54.1%) reported than females 
during 1997 to 2008 (www.ktl.fi, accessed February 2009); male predominance has also 
been reported elsewere (Skirrow, 1987; Samuel et al., 2004; Amato-Gauci & Ammon, 
2007; Gillespie et al., 2008; www.smittskyddsinstitutet.se, accessed February 2009). 
Campylobacter infection has in general a bimodal age distribution, with the highest 
reported incidence rate among children under four years of age (Skirrow, 1987; Samuel et 
al., 2004; Gillespie et al., 2008) and a second more modest peak in the age group 15 to 24 
years (Skirrow, 1987; Amato-Gauci & Ammon, 2007) and 20 to 29 years (Samuel et al., 
2004). A previous report from Finland reported the highest rate of domestically-acquired 
Campylobacter infection to be among those 70 to 74 years of age (Vierikko et al., 2004). 
The age distributions of all reported Campylobacter cases in Finland in 2002 and in 2008 
are shown in Figure 2. 
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Figure 2. Age distribution of all reported Campylobacter cases in Finland in 2002 and 2008 according to 
NIDR. 
 
In Finland, the majority of Campylobacter infections are of foreign origin; in 2008 
according to NIDR (M. Kuusi, personal communication), of the 4453 cases that were 
reported, 55.7% had been abroad prior to falling ill, 16.7% were of domestic origin, and the 
travelling history was unknown for 27.6%. The most common travelling destinations vary 
somewhat from year to year; in 2006 the most common destinations were Thailand, Spain, 
and Bulgaria, whereas the most common destinations in 2007 and 2008 were India, 
Thailand, and Spain (www.ktl.fi; M. Kuusi, personal communication). 
 
 
2.3.2 Sources of infection 
 
Campylobacter can be transferred to humans by direct contact with contaminated animals, 
or indirectly through ingestion of contaminated food or drinking water (EFSA, 2005). The 
foodborne  routes  are  considered  to  be  responsible  for  the  vast  majority  of  cases  (EFSA,  
2005). 
 
 Campylobacter species are present in domestic pets, such as dogs and cats (Acke et al., 
2009; EFSA, 2009)   and farm animals, such as poultry (Huang et al., 2009; EFSA 2009), 
cattle (Oporto et al., 2007; Huang et al., 2009; EFSA 2009), pigs (Oporto et al., 2007; 
EFSA, 2009), and sheep (Oporto et al., 2007; EFSA, 2009). In addition, a wide variety of 
wild animals are colonized with Campylobacter; waterfowl (Luechtefeld et al., 1980), wild 
birds (Waldenström et al., 2002), voles (Fernie & Healing, 1976), and rodents (Meerburg et 
al., 2006). Other potential sources of infection are flies (Rosef & Kapperud, 1983; Hald et 
al., 2004) and seafood such as oysters (Whyte et al., 2004).  
 
Campylobacter has been identified in surface waters (Hörman et al., 2004). Different water 
environments, such as lakes, rivers, and streams, become contaminated through runoff from 
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pastures after heavy rain during the grazing periods, via farm and slaughterhouse waste 
discharge, faeces from wild birds and other animals, or treated municipal wastewaters 
(Jones, 2001). Survival in the environment outside a warm-blooded host is poor (Jones, 
2001), but recently Campylobacter was shown to reside within amoebae (Axelsson-Olsson 
et al., 2005), which may be one explanation for their survival in waters of lower 
temperature. However, chlorination of water before distribution to the public is an effective 
measure of disease prevention (EFSA, 2005). 
 
 
2.3.3 Risk factors for sporadic infections 
 
The majority of human Campylobacter infections are sporadic (WHO, 2000), but the 
sources of infection usually remain unknown. Although risk factors for human 
Campylobacter infection have been identified (Blaser, 1997), the relative contribution of 
the different risk factors to the total incidence of disease remains to be established (WHO, 
2000). The contribution of various food and non-food sources to the incidence of infection 
is country- and season-dependant, due to factors such as climate, food consumption 
patterns, food production systems, and the degree of implementation on control measures 
(EFSA, 2005). 
 
The risk factors most commonly identified in case-control studies of sporadic 
Campylobacter infections include foreign travel, eating undercooked poultry, handling 
poultry, drinking untreated or contaminated water or unpasteurized milk, eating barbecued 
meat (pork, beef, poultry), and contact with (diarrhoeic) dogs and cats, in particular puppies 
and kittens (EFSA, 2005; Olsen et al., 2008 ), Table 3. 
 
As early as 1977 poultry was identified as a risk factor for Campylobacter infection 
(Skirrow, 1977). Ever since, numerous reports have implicated poultry in different forms; 
handling poultry (Hopkins & Scott, 1983), consumption of poultry (Shorr et al., 1994; 
Evans et al., 2003; Wingstrand et al., 2006), consumption of raw or undercooked poultry 
(Eberhart-Phillips et al., 1997; Michaud et al., 2004; Stafford et al., 2007), consumption of 
poultry liver (Schorr et al., 1994),  and consumption of poultry at a restaurant or 
commercial establishment (Effler et al., 2001; Friedman et al., 2004; Michaud et al., 2004).  
Consumption of other forms of meat, such as undercooked pork (Kapperud et al., 2003), 
undercooked beef (Gallay et al., 2008), turkey (Michaud et al., 2004), and meat or sausage 
prepared at a barbecue (Kapperud et al., 1992; Studahl & Andersson, 2000; Kapperud et 
al., 2003; Neimann et al., 2003), as well as occupational exposure to raw meat or animal 
carcasses (Adak et al., 1995; Eberhart-Phillips et al., 1997) have also been identified as risk 
factors. One study identified patients with C. coli infection to more likely have eaten paté 
(Gillespie et al., 2002). 
 
Many animals are implicated as sources of sporadic infection; both domestic (Kapperud et 
al., 1992; Eberhart-Phillips et al., 1997; Friedman et al., 2004; Stafford et al., 2007) and 
farm animals (Eberhart-Phillips et al., 1997; Studahl & Andersson, 2000; Neimann et al., 
2003; Evans et al., 2003; Friedman et al., 2004), as well as occupational exposure to 
animals (Kapperud et al., 2003).  
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Travelling abroad is a well-documented risk factor for sporadic Campylobacter infection 
(Schorr et al., 1994; Eberhart-Phillips et al., 1997; Friedman et al., 2004; Wingstrand et al., 
2006). In a recent Finnish study, 77% of Campylobacter patients had been abroad; the most 
common destinations being Spain and Bulgaria (Feodoroff et al., 2009). Use of medication 
prior to falling ill has been associated with sporadic Campylobacter infection as well; prior 
use  of  antibiotics  (Neal  et al., 1996; Effler et al., 2001) and prior use of proton pump 
inhibitors (Neal et al., 1996; Neal & Slack, 1997), although results suggesting otherwise 
also exist (Kapperud et al., 1992; Evans et al., 2003). Host characteristics may play a role 
in the development of Campylobacter infection; one study showed that persons infected 
with human immunodeficiency virus (HIV) were more frequently infected with 
Campylobacter than individuals not infected with HIV (Angulo & Swerdlow, 1995) and a 
recent study found Campylobacter infection more frequently among patients with severe 
primary hypogammaglobulinemia with no IgA production than in patients with residual 
IgA production (Oksenhendler et al., 2008). Diabetes mellitus has also been recognized as a 
risk factor for campylobacteriosis (Neal & Slack, 1997). 
 
Some studies have identified factors that are associated with reduced risk of Campylobacter 
infection, such as swimming (Kapperud et al., 2003), eating fresh fish (Stafford et al., 
2007), eating mutton or lamb (Kapperud et al., 2003; Evans et al., 2003), eating fresh fruits, 
vegetables, or berries (Kapperud et al., 2003; Wingstrand et al., 2006; Stafford et al., 
2007), eating curd or cottage cheese (Schorr et al., 1994), drinking delivered milk (Neal & 
Slack, 1997), and occupational contact with animals (Adak et al., 1995). Food preparation 
practices that prevent risk of cross-contamination such as washing hands and/or washing 
the cutting-board after preparing chiken has been reported to reduce risk of 
campylobacteriosis (Friedman et al., 2004). 
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Table 3. Risk-factors identified in case-control studies for sporadic Campylobacter infection* 
Year  Country                No of  Food-related risk factors             Other risk factors; animal contacts, foreign travel, medication  
                                                         cases/controls      
 
 
1989-1990 Norway1  52/103  Consumption of sausage at a  barbecue,            Daily contact with a dog    
                                                                                                eating poultry bought raw 
 
1990-1991 UK2  598/738                 Occupational exposure to raw meat, drinking untreated         Contact with a pet with diarrhoea     
                     water 
 
1994-1995 New Zealand3 621/621  Consumption of raw or undercooked chicken, chicken          Foreign travel, rainwater as a source of water at home, contact with puppies
                                                                                eaten at restaurant, consumption of raw dairy products                   and cattle (particularly calves) 
     
1994-1995 UK4  313/512  Eating chicken, drinking milk with tops damaged           Foreign travel, diabetes mellitus, medication with omeprazole, contact with  
      by a bird               puppies 
 
1995  Sweden5  101/198  Drinking raw milk, eating chicken,            Living or working on a farm, daily contact with chickens or   
eating pork with bones, barbecuing            hens    
 
1996-1997 Australia6 81/144  Consumption of mayonnaise             Ownership of pet puppies and pet chickens  
                  
1996-1997 Denmark7 282/319  Consumption of undercooked poultry, consumption of red            Foreign travel, daily contact with cattle, pigs, and poultry   
      meat at barbecue, consumption of grapes, drinking raw milk                     
 
1999-2000 Norway8  212/422  Eating at a barbecue, eating poultry bought raw,            Occupational exposure to animals  
      eating undercooked pork, drinking undisinfected water      
       
2000-2001 Denmark9 107/178  Eating fresh unfrozen chicken             Travel to southern Europe and outside Europe   
       
2001  UK10  213/1144  Eating chicken, eating salad vegetables (tomatoes, cucumbers)      Direct contact with cows or calves  
      drinking bottled water, eating from a fried chicken outlet 
 
2001-2002 Australia11               881/833    Consumption of undercooked chicken and offal           Ownership of domestic chickens and domestic dogs aged < 6 months 
  
    
*Adopted from Olsen et al., 2008 
1Kapperud et al., 1992; 2Adak et al., 1995; 3Eberhart-Phillips et al., 1997; 4Neal & Slack, 1997; 5Studahl & Andersson, 2000; 6Tenkate & Stafford, 2001;7Neimann et al., 2003; 8Kapperud et 
al., 2003;  9Wingstrand et al., 2006; 10Evans et al., 2003; 11Stafford et al., 2007 
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2.3.4 Seasonality 
 
Campylobacter infections show a consistent seasonal pattern with a well defined seasonal 
peak  in  the  summer  months  of  July,  August,  and  September  in  some  countries  (Skirrow,  
1982; Nylen et al., 2002; Kovats et al., 2005; Amato-Gauci & Ammon, 2007; EFSA, 
2009). In Finland, previous studies have identified a seasonal peak, particularly in July and 
August, for domestically-acquired sporadic Campylobacter infections (Hänninen et al., 
1998; Rautelin & Hänninen, 2000). The exceptionally high number of Campylobacter cases 
(n= 480) in December 2007 is explained by a water-borne outbreak in Nokia, Finland 
(Figure 3). 
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Figure 3. Seasonality of Campylobacter infections in Finland from 2000 to 2008 according to NIDR 
 
 
2.3.5 Outbreaks 
 
Although most Campylobacter cases are sporadic, outbreaks do occur. Outbreaks have 
most commonly been associated with the consumption of raw milk (Djuretic et al., 1997; 
Peterson, 2003; Heuvelink et al., 2009) or untreated or contaminated water (Melby et al., 
2000; Frost et al., 2002; Smith et al., 2006). Several water-borne outbreaks have been 
reported from Finland (Hänninen et al., 2003; Kuusi et al., 2005) and Campylobacter 
accounted for three of 14 water-borne outbreaks between 1998 and 1999 (Miettinen et al., 
2001). The most recent water-borne outbreak, caused by leakage of sewage into the water 
supply system, was in December 2007 in Nokia, Finland, affecting approximately 8000 
cases (EFSA, 2007b); several pathogens including Campylobacter were involved. Another 
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two C. jejuni-caused outbreaks occurred in Finland in 2007; one associated with the 
consumption of raw unpasteurized milk and the other with the consumption of lettuce 
(EFSA, 2007b).   
 
Over time the reported sources of outbreaks have changed in comprehensiveness and 
foodstuffs tend to be implicated in approximately 50% of the cases (Table 4). 
 
 
Table 4. Comprehensiveness of reported sources of outbreaks between 1978 to 2004 (adopted from Olsen et 
al., 2008) 
 
Time period (years) 
 
Source of outbreak, comprehensiveness (%) 
1978 to 1987 
1988 to 1996 
1998 to 2004 
 
Unpasteurized milk and water, 56% 
Foods, 83% 
Dairy products and drinking water, 49% 
Foods, 48% (of which 44% attributable to poultry) 
 
 
In 2006, there were in all 400 reported Campylobacter outbreaks in the European Union, 
affecting 1304 persons from 17 different countries (EFSA, 2007a). The majority were 
household outbreaks (71%), followed by restaurants and canteens or workplace catering 
outbreaks. The sources implicated in these outbreaks are listed in Table 5. In a large 
proportion of outbreaks, the source remained unknown. 
 
 
Table 5. Some food-related sources implicated in Campylobacter outbreaks in 2006 (adopted from The 
European Food Safety Authority, 2007a) 
 
Source 
 
No of outbreaks (%)       No of people  
affected/hospitalized 
Unspecified meat 
Broiler meat 
Dairy products 
Fish/fish products 
Eggs/egg products 
Other poultry meat, turkey 
Pig meat/products 
Mixed food/buffet 
Milk 
Fruits/berries/fruit juice 
Unknown 
92 (23.0) 
41 (10.3) 
25 (6.3) 
16 (4.0) 
13 (3.3) 
10 (2.5) 
8 (2.0) 
4 (1.0) 
3 (0.8) 
1 (0.3) 
178 (44.5) 
275/2 
135/10 
62/1 
34/0 
19/3 
103/11 
107/4 
34/1 
6/1 
4/0 
442/30 
 
 
2.3.6 Burden of illness 
 
Campylobacter is the leading cause of bacterial gastroenteritis in the industrialized world. 
Samuel and colleagues (Samuel et al., 2004) estimated that 1.4 to 2.3 million people 
become infected in the United States each year, corresponding to an annual incidence of 
500 to 850 infections per 100 000 persons. The burden of acute disease is evident.  
Havelaar and collegues (Havelaar et al., 2000) estimated the acute disease burden from 
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campylobacteriosis to constitute approximately one-third; the rest was linked to residual 
symptoms of GBS and increased mortality. In the United States it has been estimated that 
the fatality-rate of culture-confirmed Campylobacter infection is 0.1% (Mead et al., 1999), 
whereas data on the Danish population gives an estimated fatality-rate of 0.5% (Mølbak & 
Havelaar, 2008). 
 
 
2.3.7 Occurrence of serotypes and genotypes 
 
In Finland, the same C. jejuni serotypes were commonly identified during the seasonal peak 
from July to September, although there was annual variation in the relative proportion of 
predominant serotypes (Rautelin & Hänninen, 1999; Kärenlampi et al., 2003; Vierikko et 
al., 2004). Some of these predominant serotypes, Pen 1,44, Pen 2, and Pen 4-complex, have 
also been found relatively often in human fecal samples in Denmark (Fussing et al., 2007), 
England (Fricker & Park, 1989), and New Zealand (Hudson et al., 1999). Other common 
serotypes in Finland, Pen 6,7, Pen 12, and Pen 27, have been less common in those studies, 
although a Norweigan study reported serotype Pen 6,7 to be among the most common ones 
(Melby et al., 1985).  
 
Genotyping methods, such as PFGE, can be used to study the epidemiology of 
Campylobacter infections and are considered more discriminatory than serotyping 
methods; several genotypes can be found within one serotype (Rautelin & Hänninen, 1999; 
Wassenaar & Newell, 2000). A Finnish study from 1998 found that five predominant PFGE 
types covered 42% and 44% of the genotypes in an urban and a rural area, respectively 
(Hänninen et al., 1998). Furthermore, certain genotypes predominated during the summer 
seasonal peak. Another three-year study from the Helsinki area (Hänninen et al., 2000) 
identified several predominant genotypes that persisted throughout the study period. 
However, their relative proportions varied from one year to another; during a restricted 
period of time, the predominant genotypes comprised 28 to 52% of all the genotypes 
identified.  
 
 
2.4 Diagnostic methods 
 
2.4.1 Culture 
 
Stool samples are cultured in a microaerobic atmosphere containing approximately 5% 
oxygen, 10% carbon dioxide, and 85% nitrogen, for optimal recovery of most 
Campylobacter species. Some human enteropathogen Campylobacter species, such as C. 
hyointestinalis for example, require an increased hydrogen concentration for isolation. C. 
jejuni and C. coli are readily isolated on a variety of selective media, including both 
charcoal-based blood-free media or blood-containing media, such as Campy-CVA 
(cefoperazone, vancomycin, and amphotericin B) and Skirrow medium (Fitzgerald & 
Nachamkin, 2007). The use of a combination of media, including a charcoal-based one, 
achieves a higher yield of Campylobacter from stool samples (Endtz et al., 1991b), 
compared to using a single medium. If a single medium is to be used, Campy-CVA is to be 
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preferred or charcoal cefoperazone deoxycholate agar (CCDA) medium (Fitzgerald & 
Nachamkin, 2007). CCDA medium has been found most sensitive in detecting C. jejuni and 
C. coli, as compared to Skirrow medium, CAT medium (charcoal-based medium containing 
cefoperazone, amphotericin, and teicoplanin), or a filtration method (Engberg et al., 2000). 
 
Most selective media for isolation of Campylobacter contain  antibiotics  to  inhibit  the  
growth of normal enteric bacteria. Antimicrobial agents, such as cephalotin, colistin, and 
polymyxin B present in some selective media, are inhibitory to some C. jejuni and C. coli 
strains (Fitzgerald & Nachamkin, 2007). Media containing cephalotin are therefore no 
longer recommended for the primary isolation of Campylobacter (Fitzgerald & Nachamkin, 
2007). 
 
Campylobacter species are difficult to identify phenotypically because of biochemical 
inactivity, special growth requirements, and complex taxonomy. The medium used for 
primary isolation may affect the appearance of the Campylobacter colonies (Fitzgerald et 
al., 2008). Campylobacter spp. usually produces flat, irregular, spreading, grey colonies on 
most isolation media. Nonhemolytic colonies are seen on blood-containing media. For 
optimal isolation and identification of Campylobacter spp, moisture content of the media is 
essential; decreased moisture content reduces spreading and colonies may form a round 
convex and glistening appearance (Fitzgerald et al., 2008).  
 
Campylobacter species, primarily C. jejuni, C. coli, C. fetus, and C. upsaliensis, are 
occasionally isolated from blood cultures (Lastovica et al., 1989; Gazaigne et al., 2008; 
Pacanowski et al., 2008). Skirrow and collegues (Skirrow et al., 1993) estimated an average 
bacteraemia rate of 1.5 per 1000 intestinal infections; the highest rate was among patients 
aged 65 years or more (5.9 per 1000) and the lowest (0.3 per 1000) among children aged 1 
to 4 years. Of the identified species, C. jejuni and C. coli were the most prevalent (89%), 
followed by C. fetus (8.6%), and C. upsaliensis (0.8%).  
 
 
2.4.2 Serology 
 
Campylobacter infection usually causes a rapid serum antibody response (Kaldor et al., 
1983; Melby et al., 1986; Rautelin & Kosunen, 1987); antibodies appear in the serum from 
about the sixth day of illness and peak within two to four weeks to gradually decrease over 
a period of weeks to months (Kaldor et al., 1983; Black et al., 1988; Taylor et al., 1993; 
Porter et al., 2008). Rapid changes of serum IgM and especially IgA levels have been 
observed in paired-sera (Rautelin & Kosunen, 1987). Antibodies can be found in 
approximately 80% of enteritis patients (Taylor et al., 1993). During the first weeks of 
infection faecal IgA antibodies can also be detected (Porter et al., 2008). 
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2.4.3 Antigen detection 
 
Although stool culture is the corner stone for Campylobacter diagnosis, stool antigen 
detection tests can be of use for rapid non-culture diagnosis for patients needing early 
antimicrobial therapy. There are commercially available enzyme immunoassay-based sets, 
in which sensitivity varies from 69% (Tissari & Rautelin, 2007) up to 89% (Hindiyeh et al., 
2000; Dediste et al., 2003).  Specificity varies between 87% to > 97% (Hindiyeh et al., 
2000; Dediste et al., 2003; Tissari & Rautelin, 2007).  
 
 
2.4.4 DNA-based methods 
 
Molecular methods to detect Campylobacter directly from stool samples have been 
developed and these improve the ability to identify isolates to a species level (Fitzgerald & 
Nachamkin, 2007). Amplification techniques, such as multiplex-PCR, have been used to 
directly differentiate C. jejuni and C. coli from stool samples (Persson & Olsen, 2005). 
 
 
2.5 Antimicrobial susceptibility  
 
There are different methods for testing the susceptibility of a bacterial isolate to 
antimicrobial  agents;  dilution  (broth,  agar)  and  disk  diffusion  methods,  and  the  E-test  
(PDM  Epsilometer,  AB  Biodisk,  Solna,  Sweden).  Several  different  variations  of  these  
methods have been used for Campylobacter.  
 
 
2.5.1 Minimal inhibitory concentration 
 
Minimal inhibitory concentration (MIC) is defined as the lowest concentration of an 
antimicrobial agent that prevents visible growth of a microorganism in an agar or broth 
dilution susceptibility test (CLSI, 2006).  Antimicrobial agents are usually tested at twofold 
dilutions, although the concentration ranges used may vary with the drug, the organism 
being tested, and the site of infection (Jorgensen & Turnidge, 2007). Ranges should 
encompass the concentrations defining the interpretive categories (susceptible, 
intermediate, and resistant) and also the ranges that include the expected MICs for quality 
control reference strains. The major disadvantage with the agar dilution method is that it is 
time-consuming and labour-intensive. 
 
An agar dilution method, using Mueller-Hinton agar supplemented with 5% defibrinated 
sheep blood, for susceptibility testing of Campylobacter spp. developed by McDermott and 
colleagues (McDermott et al., 2004) was recognized by the Clinical and Laboratory 
Standards Institute as the standard antimicrobial susceptibility testing method for 
thermophilic Campylobacter species (CLSI, 2005). This method, using C. jejuni ATCC 
33560 as the quality control organism, was developed for five antimicrobials 
(ciprofloxacin, doxycycline, gentamicin, erythromycin, and meropenem) establishing their 
quality control (QC) ranges. CLSI has also quite recently approved a broth dilution method, 
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giving QC ranges for C. jejuni ATCC 33560 (CLSI, 2006). This publication also includes 
interpretive criteria for erythromycin, ciprofloxacin, doxycycline, and tetracycline.  
 
 
2.5.2 Disk diffusion 
 
For disk diffusion commercially prepared filter paper disks impregnated with a specified 
single  concentration  of  antimicrobial  agent  are  applied  to  the  surface  of  an  agar  medium  
that has been inoculated with the test organism. For Campylobacter, a Mueller-Hinton agar 
with 5% sheep blood inoculated with an equivalent of 0.5 McFarland standard is 
recommended (CLSI, 2006). The drug in the disk diffuses through the agar and the 
concentration of antimicrobial decreases logarithmically, creating a gradient of drug 
concentration in the agar medium. Concomitant to the drug diffusion, bacteria inoculated 
onto the surface that are not inhibited by the drug, continue to multiply forming a visible 
growth area. In areas where the concentration of the drug is high enough to be inhibitory, 
no growth occurs, forming a zone of inhibition around each disk (Jorgensen & Turnidge, 
2007). 
 
The advantages of the disk diffusion method include simplicity, low cost, and high degree 
of flexibility in the selection of agents tested (Jorgensen & Turnidge, 2007; Gaudreau et al., 
2007). Furthermore, the qualitative interpretive category results of “susceptible”, 
“intermediate”, and “resistant” are easily understood by the clinician. The MIC and the 
zone diameter of inhibition are inversely correlated; the more susceptible the 
microorganism is to the antimicrobial agent, the lower the MIC and the larger the zone of 
inhibition. The CLSI has approved a disk diffusion method for erythromycin and 
ciprofloxacin; a disk diffusion zone of 6 mm indicates resistance and any appearance of a 
zone of inhibition requires MIC determination (CLSI, 2006). Gaudreau and colleagues 
(Gaudreau et al., 2007) reported the disk diffusion method to be reliable for C. jejuni for 
erythromycin and ciprofloxacin as compared to agar dilution. 
 
 
2.5.3 E-test 
 
The E-test is a commercial method for quantitative antimicrobial susceptibility testing that 
combines the simplicity of agar diffusion with the ability to produce an MIC (Jorgensen & 
Turnidge, 2007). It is based on diffusion of a preformed antimicrobial gradient applied to 
one side of a plastic strip into an agar medium (Jorgensen & Turnidge, 2007). For 
Campylobacter, a 0.5 McFarland standard suspension of isolate is swabbed onto a Mueller-
Hinton agar with 5% sheep’s blood for inoculation. Following incubation in microaerobic 
conditions, the MIC is read directly from a scale on the E-test strip at the point where the 
zone of growth inhibition intersects the strip. The E-test has compared favourably with agar 
dilution methods for several antimicrobials (Baker, 1992; Huang et al., 1992), although Ge 
and colleagues (Ge et al., 2002) reported the correlation to vary depending on the 
antimicrobial agents being tested; erythromycin and ciprofloxacin correlated well. 
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2.5.4 Antimicrobial susceptibility and resistance 
 
C. jejuni and C. coli  are almost universally resistant to penicillins, cephalosporins (except 
for a few third-generation cephalosporins), trimethoprim, sulfamethoxazole, vancomycin, 
and rifampicin (Fitzgerald et al., 2008).  Originally, C. jejuni and C. coli were susceptible 
to erythromycin, tetracyclines, aminoglycosides, chloramphenicol, and clindamycin 
(Vanhoof et al., 1980; McNulty, 1987). However, resistance to a variety of antimicrobials 
has been reported since, namely fluoroquinolones (Rautelin et al., 1991; Endtz et al., 
1991a). 
 
C. jejuni is generally susceptible to erythromycin, with resistance rates varying from 0 to 
12% (Gaudreau & Gilbert, 2003; Gibreel & Taylor, 2006). Macrolide resistance among 
Campylobacter has remained stable (Sánchez et al., 1994; Smith et al., 1999; Engberg et 
al., 2001; Rautelin et al., 2003; Engberg et al., 2004). For C. coli, erythromycin resistance 
rates are much higher, ranging from 0 to 68% (Aarestrup et al., 1997; Engberg et al., 2001; 
Isenbarger et al., 2002; Engberg et al., 2004; Gibreel & Taylor, 2006). In Finland, reduced 
susceptibility to erythromycin has been quite rare among both domestically-acquired and 
foreign isolates (Rautelin et al., 2003). The origin of the resistant strains has been linked to 
veterinary use of antimicrobials (Engberg et al., 2001). 
 
Other macrolides, such as clarithromycin and azithromycin, have showed similar 
susceptibility patterns as erythromycin (Taylor & Chang, 1991; Sánchez et al., 1994; 
Murphy et al., 1996), also with higher resistance rates among C. coli as compared to C. 
jeuni (Sánchez et al., 1994). Hoge and colleagues (Hoge et al., 1998) reported of an 
increase in azithromycin resistance rates in Thailand. However, other reports have shown 
Campylobacter to be somewhat more susceptible to azithromycin than erythromycin 
(Rautelin et al., 1993; Gomez-Garces et al., 1995) and roxithromycin could be the least 
active (Gomez-Garces et al., 1995). 
 
Macrolide antimicrobials produce their antibacterial effect by inhibiting bacterial protein 
synthesis  by  targeting  the  50S  subunit  of  the  bacterial  ribosome  (Ackermann  &  Rodloff,  
2003). Two mechanisms are involved in macrolide resistance in Campylobacter; target 
modification and efflux. Target modification involves chromosomal mutations in the 23S 
rRNA gene or the genes encoding ribosomal proteins. Several point mutations in the 23S 
rRNA have been associated with Campylobacter resistance to macrolides (Engberg et al., 
2001; Jensen & Aarestrup, 2001). Efflux-mediated macrolide resistance is mediated 
through efflux-pumps that reduce accumulation of the drugs in bacterial cells (Gibreel & 
Taylor, 2006). 
 
Telithromycin was the first ketolide introduced into clinical practice. Ketolides are 
derivatives of erythromycin specifically developed for the treatment of community-
acquired respiratory infections (Ackermann & Rodloff, 2003). The in vitro activity against 
common atypical respiratory pathogens (Mycoplasma pneumoniae, Chlamydophila 
pneumoniae, Bordetella spp., Legionella spp.), Gram-positive aerobes, and Gram-negative 
respiratory pathogens (Moraxella catarrhalis, Haemophilus influenzae) has been good 
(Ackermann & Rodloff, 2003). Telithromycin has also been reported to be active against 
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several gram- positive and negative anaerobic bacteria such as Clostridium spp., 
Peptostreptococcus spp., and Bacteroides spp. (Ackermann & Rodloff, 2003). Felmingham 
& Farrell, however, reported minimal activity against Gram-negative non-respiratory 
pathogens including Campylobacter (Felmingham & Farrell, 2006). 
 
The use of fluoroquinolones (mainly enrofloxacin) in veterinary medicine has correlated 
with an increase of quinolone-resistance in Campylobacter in food animals, especially 
poultry and most importantly, in human Campylobacter infections (Endtz et al., 1991a). 
The first reports of fluoroquinolone resistance appeared in the beginning of the 1990’s 
(Rautelin et al., 1991, Endtz et al., 1991a) and thereafter a remarkable increase followed 
(Reina et al., 1994; Hoge et al., 1998; Smith et al., 1999; Engberg et al., 2001). In Finland, 
resistance to fluoroquinoles has mainly occurred among Campylobacter isolates of foreign 
origin (Rautelin et al., 2003). According to the European Centre for Disease Prevention and 
Control (ECDC) report from 2007 (Amato-Gauci & Ammon, 2007), 37-48% of C.  jejuni 
and C. coli strains were resistant to ciprofloxacin in 2005 in Europe. A recent report from 
Spain reported a ciprofloxacin resistance rate of 84% (Rodríguez-Avial et al., 2006).  
 
Fluoroquinolones function by interacting with two target enzymes; DNA gyrase and 
topoisomerase. Fluoroquinolone resistance in C. jejuni appears primarily to be caused by 
mutations in the gyrA gene (Engberg et al., 2001). Evidence of efflux of fluoroquinolones, 
as a resistance mechanism, in C. jejuni has also been reported (Engberg et al., 2001). These 
two mechanisms function synergistically to maintain a high fluoroquinolone-resistance 
level in clinical isolates (Ge et al., 2005). 
 
ß-lactamase producing strains of C. jejuni and C. coli have been identified (Tajada et al., 
1996), and resistance is seen principally against penicillins and cephalosporins, although 
moderate susceptibility to third generation cephalosporins has been reported (Fitzgerald et 
al., 2008).  Ampicillin is not recommended for treatment of C. jejuni infection due to high 
rates of resistance (Gallay et al., 2007). The reported rates of resistance to amoxicillin-
clavulanic acid have been low (Gomez-Garces et al., 1995; Tajada et al., 1996; Gaudreau & 
Gilbert, 2003; Hakanen et al., 2003b; Rodríguez-Avial et al., 2006). Imipenem 
susceptibility is high (Tajada et al., 1996; Gaudreau & Gilbert, 2003; Hakanen et al., 
2003b; Gallay et al., 2007) and imipenem may be used to treat systemic infections.  
 
Reports of tetracycline resistance vary from 11% to 70% among countries (Sagara et al., 
1987; Aarestrup et al., 1997; Hakanen et al., 2003b; Rodríguez-Avial et al., 2006) and 
increasing rates of resistance have been reported (Gaudreau & Gilbert, 1998; Gallay et al., 
2007). In Finland, doxycycline resistance rates were reported to be 15% to 17% (Rautelin et 
al., 1991) and Sweden has reported increasing rates (Sjögren et al., 1992; Sjögren et al., 
1997). The activity of clindamycin against C. jejuni is equivalent to that of erythromycin 
(Rodríguez-Avial et al., 2006; Fitzgerald et al., 2008). Aminoglycosides, such gentamicin, 
have shown good activity against Campylobacter (Rautelin et al., 1991; Gaudreau & 
Gilbert, 2003).  
 
Multidrug resistance appears to be more frequent nowadays among Campylobacter isolates 
(Fitzgerald et al., 2008). A recent report found 62% of strains to be resistant to both 
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ciprofloxacin and tetracycline (Rodríguez-Avial et al., 2006), whereas Hakanen and 
colleagues (Hakanen et al., 2003b) reported 68% of co-resistance. Gaudreau & Gilbert 
(Gaudreau & Gilbert, 2003) reported an increase in co-resistance to ciprofloxacin and 
tetracycline, ranging from 6% to 25%. Ciprofloxacin co-resistance with erythromycin or 
ampicillin has also been reported (Gaudreau & Gilbert, 2003; Hakanen et al., 2003b). 
 
 
2.6 Clinical aspects of Campylobacter jejuni/coli  infection 
 
2.6.1 Disease description 
 
Campylobacter enteritis is an acute diarrhoeal disease with clinical manifestations like 
those of other enteropathogens, such as Salmonella and Shigella. Clinically these infections 
cannot be distinguished from each other. Campylobacter causes acute inflammatory 
enteritis, commonly extending down the intestine to affect the colon and rectum (Lambert 
et al., 1979; Blaser et al., 1980; Colgan et al., 1980). Terminal ileitis and cecitis with 
mesenteric adenitis is common (Puylaert et al., 1989). For infection to become established, 
Campylobacter must  survive  the  acidic  conditions  in  the  stomach  and  then  colonize  the  
small intestine. Colonization of the gut mucosa depends on unimpaired bacterial mobility 
and the ability of bacteria to attach to the surface of mucosal cells (Wooldridge & Ketley, 
1997). Several virulence factors for Campylobacter have been suggested, but are not well 
understood (Ketley, 1997; Wassenaar & Blaser, 1999; van Vliet & Ketley, 2001; Tracz et 
al., 2005; Louwen et al,. 2006). 
 
The infective dose of C. jejuni is thought to be low; experimental human infections have 
been achieved with doses as low as 500-800 bacteria (Robinson, 1981; Black et al., 1988). 
The mean incubation period is approximately 3 days, with a range of 1-8 days (Svedhem & 
Kaijser, 1980; Finch & Blake, 1985; Blaser, 1997; Blaser & Engberg, 2008).  
 
The clinical picture of Campylobacter enteritis depends on the virulence of the infecting 
strain (Tracz et al., 2005), the infective dose (Black et al., 1988; Medema et al., 1996), and 
the susceptibility of the patient (Melamed et al., 1983; Johnson et al., 1984; Peterson, 1994; 
Neal et al., 1996; Neal et al., 1997; Gillespie et al., 2006). Campylobacter enteritis is 
characterized by an abrupt onset with intense abdominal cramping pains, rapidly followed 
by profuse watery diarrhoea (Peterson, 1994) (Table 6). Patients experience prodromal 
symptoms with fever, headache, dizziness, myalgia, and fatigue (Drake et al., 1981; 
Peterson, 1994); these particular patients tend to have a more severe illness (Blaser & 
Engberg, 2008). Data on the disease are based on facts collected on patients sufficiently ill 
to seek medical attention but milder degrees of the illness may remain unrecorded. 
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Table 6. Clinical features of Campylobacter enteritis derived from surveys of community outbreaks (adopted 
from Blaser & Engberg, 2008) 
 
 
Symptom 
 
Frequency of symptom, 
range (%) 
Diarrhoea 
Abdominal pain 
Fever 
Headache 
Myalgia 
Vomiting 
Blood in feces 
 52-100 
56-99 
6-75 
6-69 
28-59      
1-42 
0.5-32           
 
 
Over 50% of the patients requiring emergency treatment have ?10 bowel movements per 
day (Blaser & Engberg, 2008). Bloody diarrhoea appears approximately one to two days 
after the start of the diarrhoea, with a varying incidence of 15 to 30% for outpatient and 
hospitalized patients, respectively (Blaser & Engberg, 2008). A review from 1994, reported 
the incidence of bloody diarrhoea to vary from 6 to 57% (Peterson, 1994). Nausea is 
common, but vomiting occurs less frequently (Skirrow, 1977; Peterson, 1994; Blaser & 
Engberg, 2008). Gillespie (Gillespie et al., 2006) found bloody diarrhoea and nausea to be 
associated with longer illness and more frequent hospitalization. The diarrhoea begins to 
ease after three to four days, although abdominal pain may persist longer (Skirrow, 1977). 
Symptoms usually resolve within a week, but stool samples remain positive for several 
weeks. Relapses may occur in approximately 15% of the patients (Pitkänen et al., 1983). 
The proportion of hospitalized patients varies in different reports (0.5 to 32%), the average 
being 5 to 10% (Blaser & Engberg, 2008). 
 
 
2.6.2 Acute complications 
 
Campylobacter enteritis can cause a variety of intestinal and extraintestinal complications 
(Table 7). Bacteraemia has been calculated to have an average incidence rate of 1.5 per 
1000 Campylobacter infections, with a range of 0.3/1000 in children aged 1 to 4 years to 
5.9/1000 in patients aged 65 years or more (Skirrow et al., 1993). 
 
The association between Campylobacter enteritis and GBS, an acute paralytic disease of the 
peripheral nervous system, was first reported in the beginning of the 1980’s (Rhodes & 
Tattersfield, 1982; Molnar et al.,  1982).  It  is  a  rare  complication,  with  an  estimated  
incidence of < 2 per 10 000 Campylobacter infection cases (Tam et al., 2006), although 
higher incidence rates have been reported from northern China and Bangladesh (Jacobs et 
al., 2008). At present, C. jejuni is the predominant preceding infection in GBS (Tam et al., 
2007). It has been suggested that the infection triggers the production of cross-reactive 
antibodies to gangliosides, which results in demyelination of the peripheral nerves (Jacobs 
et al., 2008). GBS has been associated with C. jejuni serotype Pen 19 (Kuroki et al., 1993, 
Chatzipanagiotou et al., 2003). Miller-Fisher syndrome (MFS), a subform of GBS 
characterized by areflexia, ataxia, and ophthalmoplegia (Fisher, 1956), has been connected 
to C. jejuni serotype Pen 2 (Neisser et al., 1997). 
 30 
Table 7. Acute complications associated with Campylobacter infection 
 
Organ system 
 
Reference 
Intestinal complications 
  “Pseudo-appendicitis” (terminal ileitis and  mesenteric adenitis) 
    Appendicitis 
   Abdominal emergency; bowel obstruction 
   Colitis 
   Inflammatory bowel disease (IBD) 
   
   Irritable bowel syndrome (IBS) 
   Toxic megacolon 
   Intestinal haemorrhage 
Extraintestinal complications 
   Hepatitis 
   Cholecystitis 
   Pancreatitis 
   Nephritis 
   Hemolytic uremic syndrome 
   Cystitis 
   Abortion and perinatal infection 
   
   Peritonitis 
   Myocarditis, myopericarditis, atrial fibrillation 
    
   Splenic rupture 
   Focal infections; prosthetic hip infection, myositis 
    
   Meningitis, subdural sepsis 
   Cellulitis 
 
Puylaert et al., 1989 
Mégraud et al., 1982  
Pönkä et al., 1981; Bentley et al., 1985 
McKendrick et al., 1982 
Ternhag et al., 2008;  
García Rodríguez et al., 2006 
Smith & Bayles, 2007 
Jackson et al., 1999 
Michalak et al., 1980 
 
Korman et al., 1997 
Dakdouki et al., 2003 
Pönka & Kosunen, 1981 
Rautelin et al., 1987 
Chamovitz et al., 1983 
Feder et al., 1986 
Denton & Clarke, 1992;  
Krishnaswamy et al., 1991 
Vermeij C et al., 1996 
Pönkä et al., 1980; Hannu et al., 2005; 
Kotilainen et al., 2006 
Frizelle & Rietveld, 1994 
Peterson et al., 1993;  
Dawson & Davidson, 2001 
Norrby et al., 1980; Ritchie et al., 1987 
Monselise et al., 2004 
 
 
 
2.6.3 Reactive arthritis and other musculoskeletal complications 
 
The term reactive arthritis (ReA) was first introduced by Ahvonen in 1969 (Ahvonen et al., 
1969) to describe a non-purulent joint inflammation, triggered by an infection elsewhere in 
the body, but since then the definition has been modified (Sieper & Braun, 1999). ReA 
belongs to the spondyloarthropathies; a group of diseases which resemble each other (Table 
7), comprising ankylosing spondylitis, psoriatic arthritis, arthritis associated with 
inflammatory bowel disease, and juvenile onset arthritis (Dougados et al., 1991; Amor, 
1998).  These diseases share an association with the genetic marker HLA-B27, the absence 
of rheumatoid factor, and frequently occurring extra-articular symptoms (Table 8) 
(Leirisalo-Repo, 2005). 
 
 
 
 
 
 
 
 31 
Table 8. European Spondyloarthropathy Study Group classification criteria for spondyloarthritis (adopted 
from Dougados et al., 1991) 
 
Criteria for spondyloarthropathy 
 
1. Inflammatory spinal pain or synovitis  (asymmetric, predominantly in the lower limbs)                                   
 and one of the following    
2. Positive family history 
    Psoriasis 
    IBD 
    Acute diarrhoea or urethritis or cervicitis preceding the arthritis 
    Alternate buttock pain 
    Enthesopathy 
    Radiological sacroilitis          
 
ReA is usually triggered by a gastrointestinal or urogenital infection and can be caused by 
several pathogens such as Salmonella, Shigella, Yersinia, Campylobacter, and Chlamydia 
trachomatis (Keat, 1983). Other triggering pathogens, such as Chlamydophila pneumoniae 
(Saario & Toivanen, 1993; Braun et al., 1994), Chlamydophila psittaci (Bhopal & Thomas, 
1982), and Clostridium difficile (Hannonen et al., 1989) have also been identified. The 
following Campylobacter spp. have been identified to cause ReA: C. coli (Hannu et al., 
2002), C. fetus (Urman et al., 1977), C. jejuni (Berden et al., 1979; Kosunen et al., 1981), 
and C. lari (Goudswaard et al., 1995), with C. jejuni being the most common. The 
triggering infection can also be asymptomatic (Leirisalo-Repo, 2005). 
 
The typical clinical features of ReA are characterized by asymmetrical oligoarthritis, often 
in the large joints of the lower extremities (Leirisalo-Repo, 2005). The symptoms, which 
typically start one to two weeks after the triggering infection, can include pain, swelling, 
redness, warmth, and movement restriction of the joints. Typical extra-articular symptoms 
are presented in Table 9. Patients can present with enthesopathy alone or in conjunction 
with ReA (Hannu et al., 2002). 
 
Table 9. Extra-articular symptoms associated with ReA* 
 
Organ system or body part Features 
 
Eyes 
Urogenital system 
Skin 
Heart 
Kidney 
Nail  
Mucocutaneous 
Soft tissues 
Conjunctivitis, iritis, anterior uveitis, keratitis 
Urethritis, cervicitis, prostatitis 
Keratoderma blennorhagica, keratitis, erythema nodosum    
Carditis, aortic valve disease 
IgA glomerulonephritis, proteinuria, hematuria 
Nail dystropyhy 
Oral ulcers, balanitis circinata 
Plantar fasciitis, enthesitis, tendinitis, bursitis 
*According to; Inglis et al., 1994; Hill Gaston & Lillicrap, 2003; Leirisalo-Repo, 2005 
 
 
However, no universal agreement has been reached on the diagnostic criteria of ReA. Keat 
(Keat, 1983) suggested that the term ReA should apply to the whole spectrum of infection-
triggered arthritis and the term Reiter’s syndrome (RS) should be reserved for the classical 
triad; arthritis, conjunctivitis, and urethritis.  
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ReA occurs in about 1 to 5% of Campylobacter cases (Pope et al., 2007) although a Finnish 
study reported up to 7%, with an estimated annual incidence of 4.3 per 100 000 patients 
(Hannu et al., 2002).  Since Campylobacter is the most common bacterial enteropathogen 
in the Western world (Blaser, 1997), Campylobacter ReA is increasingly important 
(Söderlin, et al.; 2003, Leirisalo-Repo, 2005). A severe course of enteritis has been linked 
to a higher incidence of ReA (Locht & Krogfelt, 2002). In a Finnish 10- year follow-up 
study  of  ReA  and  RS,  the  average  duration  of  arthritis  was  3  to  5  months,  and  
approximately 15% developed chronic sequealae or progressed to ankylosing spondylitis 
(Leirisalo et al., 1982). Although genetic factors may play a role, recent studies have not 
found an association between HLA-B27 positivity and risk of acquiring ReA after 
Campylobacter infection (Hannu et al., 2002; Schiellerup et al., 2008; Townes et al., 2008). 
 
 
2.6.4 Treatment 
 
Campylobacter enteritis is usually a self-limiting disease and in most cases no specific 
treatment is needed (McNulty, 1987; Blaser & Engberg, 2008). Antimicrobial therapy plays 
a limited role, since patients usually seek medical advice after they have been ill for several 
days and the symptoms may have settled spontaneously by the time of microbiological 
diagnosis (Anders et al., 1982; Mandal et al., 1984). Antimicrobial treatment may, 
however, play a role in cases of complicated disease; prolonged, relapsed or unusually 
severe enteritis (Blaser et al., 1980; Bentley et al., 1985; Thielman & Guerrant, 2004), 
bacteraemia (Pacanowski et al., 2008), and for immuno-compromised patients (Blaser, 
1997). Some studies report that antimicrobial treatment shortens the duration of 
Campylobacter diarrhoea (Salazar-Lindo et al., 1986; Mattila et al., 1993; Kuschner et al., 
1995; Ternhag et al., 2007), whereas others have not found this effect (Williams et al., 
1989). 
 
Erythromycin was the first antimicrobial agent to be used for Campylobacter enteritis and 
macrolides remain the drugs of choice (McNulty, 1987; Smith et al., 1999; Guerrant et al., 
2001; Blaser & Engberg, 2008). Erythromycin resistance rates have remained low and 
relatively stable in Finland, Canada, Denmark, and France (Engberg et al., 2001; Rautelin 
et al., 2003; Gaudreau & Gilbert, 2003; Gallay et al., 2007). Others report of increasing 
macrolide resistance among human isolates (Murphy et al., 1996; Hoge et al., 1998) and 
alternative treatments are considered. Even regional differences of macrolide resistance 
rates within the same country have been reported (van Hees et al., 2007). In addition, some 
studies have reported development of resistance to macrolides (erythromycin and 
azithromycin) during therapy (Pitkänen et al., 1982; Funke et al., 1994; Tribble et al., 
2007). However, in a double-blind trial comparing single-dose azithromycin to 3-day 
azithromycin and 3-day levofloxacin regimens, single-dose azithromycin was shown to be 
the preferred antimicrobial for empirical treatment of traveler’s diarrhoea in Thailand 
(Tribble et al., 2007). In this study microbilogical eradication of Campylobacter-caused 
infections was superior for azithromycin-treatment (100%) compared to levofloxacin-
treatment (21%), due to the high rates of fluoroquinolone resistance in Thailand. However, 
when fluoroquinolone resistant strains were excluded, an equivalent time to recovery was 
observed for levofloxacin and azithromycin (Tribble et al., 2007). 
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Fluoroquinolones may be of limited use in Campylobacter infection, due to the increased 
rates of resistance since the beginning of the 1990’s (Endtz et al., 1991a; Rautelin et al., 
1991; Gomez-Garces et al., 1995; Murphy et al., 1996; Engberg et al., 2001; Hakanen et 
al., 2003b; Engberg et al., 2004). Induction of fluoroquinolone resistance during treatment 
is well recognized (Segreti et al., 1992; Ellis-Pegler et al., 1995) and estimated to occur in 
10% to 20% of fluoroquinolone-treated patients (Fitzgerald et al,. 2008). Adler-Mosca and 
colleagues (Adler-Mosca et al., 1991) reported ciprofloxacin/norfloxacin resistance after 
only one or two administrations of fluoroquinolone. Some studies show higher rates of 
resistance to fluoroquinolones among travel-associated infections compared to 
domestically-acquired ones (Sjögren et al., 1997; Smith et al., 1999; Rautelin et al., 2003; 
Unicomb et al., 2003; Engberg et al., 2004; van Hees et al., 2007). 
 
Hakanen and colleagues (Hakanen et al., 2003b), when studying multi-resistant C. jejuni, 
suggested amoxicillin-clavulanic acid as an alternative antimicrobial for treating enteritis 
caused by multi-resistant C. jejuni, and a carbapenem, such as imipenem, for the treatment 
of life-threatening infections. Imipenem has also been suggested as the treatment of choice 
for Campylobacter bacteraemia (Gazaigne et al., 2008). Rodríguez-Avial and colleagues 
(Rodríguez-Avial et al., 2006), when studying the in vitro effect of tigecycline, suggested 
tigecycline as an alternative antimicrobial for tetracycline-ciprofloxacin resistant strains. 
Other antibiotics, such as gentamicin and clindamycin, may be listed as alternative drugs 
for the treatment of Campylobacter infections (Blaser & Engberg, 2008). 
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3. AIMS OF THE STUDY 
 
 
The  aim of  this  PhD thesis  was  to  study  the  epidemiology and  risk  factors,  bacterial  and  
host characteristics, as well as complications of sporadic domestically-acquired 
Campylobacter infections in Finland during a seasonal peak from July 1st to September 30th 
in 2002 in a multi-center study and the in vitro susceptibilities of Campylobacter isolates to 
some antimicrobials. The specific aims of the study were: 
 
 
1. To identify risk factors and possible sources of infection for domestically-acquired 
sporadic Campylobacter infections in Finnish patients.  
 
 
2. To study if a particular C. jejuni serotype, exposure factor, or demographic 
characteristic were associated with each other or with the severity of disease in 
domestically-acquired sporadic C. jejuni infections, from three geographical areas, 
representing both more urban and more rural surroundings. 
 
 
3. i) To compare the in vitro activity of telithromycin to that of erythromycin for 
         domestically-acquired Campylobacter  isolates and on isolates selected on the  
         basis of presumed resistance to erythromycin and/or ciprofloxacin, which were 
         mostly of foreign origin.  
           ii) To test the in vitro susceptibility of these isolates also to doxycycline,    
               ciprofloxacin, and moxifloxacin. 
           iii) To compare the disk diffusion method to the agar dilution method for  
                ciprofloxacin and erythromycin.                
 
 
4. To study the incidence of patient-reported complications, especially 
musculoskeletal symptoms, after sporadic domestically-acquired C. jejuni enteritis 
and possible associations between complications, antimicrobial treatment or the 
serotypes of the C. jejuni isolates. 
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4.        MATERIALS AND METHODS 
 
 
4.1 Study design, patients, and controls 
 
This multi-centre questionnaire-based cross-sectional study of sporadic domestically- 
acquired Campylobacter infections was conducted during a seasonal peak from July 1st to 
September 30th in 2002. Seven clinical microbiology laboratories serving both rural and 
urban areas participated; the Helsinki, Satakunta, and Oulu areas were considered more 
urban, with < 20% of the population living in the countryside.  Outpatients and hospital 
patients with stool culture-verified Campylobacter infection, who had not travelled abroad 
within two weeks prior to illness, were included.  
 
 
4.1.1 Case-control study (I) 
 
Three clinical microbiology laboratories serving patients in the southern, central, and 
eastern parts of Finland participated. A case-patient was defined as a person with stool 
culture positive for C. jejuni or C. coli collected during the study period. When a 
Campylobacter-positive patient was identified, personnel from the microbiology laboratory 
contacted the clinic or hospital for more information on the patient’s recent travel history. If 
the patient had not travelled abroad within two weeks before illness, the patient’s physician 
was contacted by phone and asked to send information on our study and the questionnaire 
to the patient. The patients returned the questionnaire to the researchers in a prepaid 
envelope.  
 
Two age-, sex-, and municipality-matched controls were chosen for each case-patient. 
Controls were selected from the Population Register Center, Espoo, Finland, which is an 
official register of all Finnish residents. Potential controls were contacted by mail and 
requested to fill in a questionnaire and mail it back in a prepaid envelope. If the 
questionnaire  was  not  returned  within  two  weeks,  a  new  pair  of  controls  was  chosen,  
leading  to  a  maximum  of  four  controls  per  case.  Controls  were  excluded  if  they  had  
travelled abroad two weeks prior to filling in the questionnaire. In addition, other exclusion 
criteria were prior Campylobacter infection, at least three loose stools per day, abdominal 
pain, or fever 30 days before filling in the questionnaire (WHO, 1998). 
 
In total, 316 stool culture-verified Campylobacter cases and 634 controls were identified. 
The response rates and exclusion criteria are shown in Table 10. 
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Table 10. Cases and controls; response rates and exclusion criteria, study I 
  Collection of cases and controls Cases (%) 
 
Controls (%) 
 
No of  all Campylobacter cases during the study period 
Presumably domestic cases/controls 
Returned questionnaire 
 
Excluded due to the following based on the questionnaire: 
  Foreign travel 
  Misunderstanding/missing information 
  Delay in answering > 37 days 
  Delay in answering unknown 
  Lack of matching control/case 
  Previous Campylobacter infection 
  Previous gastrointestinal symptoms* 
   
Final study set 
316 
208 
151 (73) 
 
51 
11 
3 
5 
11 
21 
- 
- 
 
100 
 
634 
309 (49) 
 
172 
17 
21 
- 
- 
76 
2 
56 
 
137 
*Following the WHO suggestion for performing Campylobacter case-controlled studies (WHO, 1998) 
 
 
The final study set comprised 100 cases and 137 matched controls. Cases and controls were 
matched in doubles (66), triples (31), and quadruples (3). Regional distribution and 
demographic characteristics of the cases and controls are presented in Table 11.  
 
 
Table 11. Demographic characteristics of cases and controls, study I 
Characteristic 
 
Cases 
n= 100 (%) 
Controls 
n= 137 (%) 
Gender 
 Female 
 Male 
Median age (years) 
Municipality 
  Helsinki 
  Kuopio 
  Joensuu 
Median delay (days) from start 
of illness of the case to filling 
in questionnaire* 
 
58 (58) 
42 (42) 
51 
 
35 (35) 
44 (44) 
21 (21) 
 
16 
 
81 (59) 
56 (41) 
51 
 
47 (34) 
62 (45) 
28 (20) 
 
32 
* The median delay between cases and controls filling in the questionnaire was 15 days. 
 
 
4.1.2 Other patients (II,  IV) 
 
In study II, patients were collected from the same three microbiology laboratories as in 
study I. The final study set comprised 114 patients with C. jejuni enteritis  (Table  12),  of  
which 75% (85/114) also participated in study I.  
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Table 12. Demographic characteristics of C. jejuni patients, study II 
Characteristic Helsinki 
N (%) 
Kuopio 
N (%) 
North Karelia 
N (%) 
Total 
N (%) 
No of patients 
Gender 
  Female 
  Male 
Median age (years) 
Month of stool sample 
  July 
  August 
  September 
Total 
39 (34) 
 
27/39 (69) 
12/39 (31) 
50 
 
19 (28) 
18 (49) 
2 (22) 
39 (43) 
53 (47) 
 
27/53 (51) 
26/53 (49) 
47 
 
34 (50) 
13 (35) 
6 (67) 
53 (47) 
22 (19) 
 
5/22 (23) 
17/22 (77) 
51.5 
 
15 (22) 
6 (16) 
1 (11) 
22 (19) 
114 
 
59 (52) 
55 (48) 
50 (range 1-88) 
 
68 (60) 
37 (33) 
9 (8) 
114 (100) 
 
 
Reasons for exclusion are seen in Table 13. 
 
Table 13. Excluded patients (n=37) of the 151 that returned the questionnaire, study II 
Excluded patients N 
 
Travelling abroad or information on travelling abroad missing 
Misunderstanding the questionnaire 
C. coli 
Unidentifiable serotype 
  Isolate not available 
  Did not react with any of the antisera tested 
  Mixed serotype  
Total 
 
13 
4 
1 
19 
8 
10 
1 
37 
 
 
In study IV, cases were collected from all seven microbiology laboratories. The final study 
set comprised 201 patients with C. jejuni enteritis (Table 14). The material was 
representative with respect to gender, age, and seasonal distribution.  
 
Table 14. Response rate and exclusion criteria for patients with C. jejuni enteritis, study IV   
 
Response rate and exclusion criteria of patients 
 
Number of cases (%) 
Received questionnaire 
Returned questionnaire 
Response rate** 
  Kuopio 
  North Karelia 
  Helsinki 
  Oulu 
  Satakunta 
  Central Finland 
Excluded patients 
  Travelling abroad 
  Returned questionnaire blank 
  Yielded C. coli 
  Simultaneous Plesiomonas shigelloides infection 
Final study set 
406* 
235 (58) 
218/340 (64) 
61/86 (71) 
25/31 (81) 
50/79 (63) 
46/74 (63) 
14/27 (52) 
22/43 (52) 
17 
8 
4 
4 
1 
201 
*17 patients did not receive a questionnaire due to failing permission (12), misplaced information (4), and one 
could not be reached. 
**Patients from one center were excluded due to exceptionally low participation rate (26%) 
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4.2 Questionnaires 
 
4.2.1 Case-control study (I)  
 
Patients received a questionnaire, regarding two weeks prior to becoming ill, including 
questions on the disease, travel in and outside of Finland, dietary intake of food items 
(meat, fish, vegetables, fruit, and dairy products), food handling, quality of drinking water, 
contact with pets and other domestic animals, and swimming in natural sources of water. A 
total of 82 exposure factors were included. Controls received similar questionnaires, 
concerning two weeks prior to the inquiry, although without specific questions concerning 
Campylobacter infection.  
 
 
4.2.2 Late-onset complications (IV) 
 
Two months after collection of Campylobacter positive stool samples, a questionnaire 
concerning possible complications connected to the enteritis was sent to the patients. The 
questionnaire inquired about musculoskeletal symptoms and symptoms from the urinary 
(dysuria, frequency, discharge) and gastrointestinal tract (prolonged diarrhoea, stomach 
ache), nervous system (nerve pain, paresthesia, nervus facialis paresis), heart (chest pain, 
arrhythmia), skin, and eyes (pain, redness, sensitivity to light, discharge).  
 
Of the patients that participated in our case-control study (I), 139 gave permission to send 
the questionnaire directly and 57 patients received the questionnaire through their 
physician. The remaining 210 patients from the other four study centres received the 
questionnaire through their physician. In addition, information on Campylobacter infection 
was collected from medical records in 111 cases who gave permission to do so (information 
only on antimicrobial therapy in another 13 cases). 
 
 
4.3 Bacterial isolates 
 
4.3.1 Domestic isolates (I-IV) 
 
Campylobacter stool isolates were cultured in the participating microbiology laboratories, 
then collected in Helsinki and stored at -70 °C before being analyzed. C. jejuni and C. coli 
were identified by positivity or negativity for hippurate hydrolysis, respectively. In studies 
I-II, 208 presumably domestic Campylobacter stool samples were collected. Of the 100 
cases comprising study I, 99 isolates yielded C. jejuni and one C. coli. In study II all 114 
isolates included were C. jejuni. A total of 393 domestic isolates were included in study III; 
379 C. jejuni isolates and 14 C. coli isolates. All 201 isolates included in study IV were C. 
jejuni. 
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4.3.2 Isolates selected on the basis of reduced antimicrobial susceptibility (III) 
 
In study III, 85 Campylobacter stool isolates (62 C. jejuni and 23 C. coli) collected at 
Helsinki University Central Hospital Laboratory in 2002 (47 isolates), 2003 (11 isolates), 
and 2004 (27 isolates), were included because of presumably reduced susceptibility, as 
based on the disk diffusion test, against erythromycin and/or ciprofloxacin. Eighty-one 
patients had been abroad. Travelling history was not known for three patients and one 
patient had not been abroad. 
 
 
4.3.3 Serotyping (II, IV) 
 
C. jejuni isolates were serotyped using a commercially available serotyping set 
(Campylobacter Antisera Seiken Set, Denka Seiken Co., Tokyo, Japan) containing 25 
antisera groups and a control serum. C. jejuni isolates were cultured on 5% horse blood 
agar plates and incubated in microaerobic conditions at 37°C for 48 hours. The HS antigens 
were extracted following the manufacturer’s instructions: bacteria were suspended into 
0.25ml of saline and 0.25ml of each extract reagent 1 and 2 were added. After incubation 
for 10 minutes at room temperature, 0.25ml of extract reagent 3 was added and the 
suspension was centrifuged for five minutes at 7000 rpm.  The supernatant was used as 
antigen solution to sensitise aldehyde-fixed chicken red blood cells (RBCs).  
 
Fixed RBCs were prepared by mixing 0.5ml of RBCs with 0.5ml of buffer solution, 
centrifuged at 3000 rpm for 10 minutes, the supernatant was discarded, and 0.5ml of buffer 
solution was added. The sensitized cells were prepared by mixing 0.5ml of fixed chick 
RBCs with 0.5ml of bacterial antigen solution and incubated for 30 minutes at 37°C, with 
occasional shaking. The solution was centrifuged at 6000 rpm for 30 seconds, the 
supernatant was discarded and 1ml of buffer solution added.  The extracted molecules 
adhere to the surface of the RBCs, referred to as sensitization. 
 
Passive hemagglutination was performed by placing one drop of each antiserum 
individually into microplate wells. One drop of control serum was used in a separate well to 
control for self-agglutination. One drop (25?l) of sensitized cell suspension was dropped 
into each well, mixed, and incubated for 30 minutes in a moisture box at room temperature. 
After 30 minutes the hemagglutination results were observed and interpreted as follows 
(Figure 4): 
 
 
 
 
 
   
RBCs sediment (dark    RBCs agglutinate to   RBCs agglutinate                 Complete  
centre), no agglutination;   some extent (light grey);   moderately (darker grey);    agglutination; 
Negative -    Weakly positive +  Moderately positive 2+    Strongly positive 3+  
Figure 4. Serotyping of Campylobacter by passive hemagglutination method  
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Only strongly (3+) or moderately (2+) positive reactions with a single antiserum were 
regarded as significant. Isolates reacting strongly/moderately to several antisera were 
considered complex serotypes and failure to agglutinate was recorded as untypeable. 
 
 
4.3.4 Antimicrobial susceptibility testing (III) 
 
 
Determination of MICs  
 
The evaluated antimicrobial agents were telithromycin (Aventis Pharma S.A., Antony, 
France), erythromycin (Sigma, St.Louis, Mo, USA), doxycycline (Orion, Espoo, Finland), 
ciprofloxacin (Bayer, Leverkusen, Germany), and moxifloxacin (Bayer). The MICs for the 
isolates were determined by an agar dilution method according to tentative guidelines 
(McDermott et al., 2004; NCCLS 2003).  
 
Mueller-Hinton agar (Oxoid Ltd., Basingstoke, United Kingdom) plates supplemented with 
5% defibrinated horse blood were used. Antibacterial agent-containing medium was 
prepared within 24 hours of use and stored overnight at room temperature. Inocula prepared 
from overnight growth on blood agar plates were suspended in 0.9% saline to obtain a 
turbidity of a 0.5 MacFarland standard and approximately 104 CFU were applied per spot 
with a multipoint inoculator. As control organisms, C. jejuni ATCC 33560 (NCCLS, 2003), 
Escherichia coli ATCC 25922, and Staphylococcus aureus ATCC 29213 were included. 
The plates were incubated in a microaerobic atmosphere (BBL CampyPak Plus, Becton 
Dickinson and Company, Sparks, MD, USA) at 36°C for 48 hours. The lowest 
concentration that completely inhibited the visible growth of the organism was regarded as 
the MIC. The ranges of the studied antimicrobials were as follows: ciprofloxacin 0.008-128 
?g/ml, erythromycin 0.125-1024 ?g/ml, telithromycin 0.015-64 ?g/ml, doxycycline 0.03-
128 ?g/ml, and moxifloxacin 0.008-128 ?g/ml. 
 
 
Disk diffusion 
 
Susceptibilities to erythromycin and ciprofloxacin were determined by disk diffusion. Agar 
plates consisting of Trypticase soy agar (BBL) and Mueller-Hinton agar (BBL) and 
supplemented with 5% horse blood were used. Inocula from overnight growth were 
suspended in sterile saline. The turbidity of suspensions was adjusted to a MacFarland 
standard of 0.5. The plates were inoculated by using a swab and disks (Oxoid) including 
erythromycin (15µg) and ciprofloxacin (5µg) were added. The plates were incubated at 
36°C in a microaerobic atmosphere for 48 hours. The zone diameter of inhibited growth 
was then recorded.  
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4.4 Statistical analyses 
 
 
4.4.1 EpiData and EpiInfo (I) 
 
In our case-control study, data entry was performed by EpiData 2.1b (EpiData Association, 
Odense, Denmark), and statistical analyses were made with EpiInfo 2002 (Centers for 
Disease Control and Prevention, Atlanta, GA). For sample-size calculation, the case-control 
ratio was 1:2. The exposure level among patients and controls was assumed to be 30% and 
15%, respectively. The study was based on the estimate that 97 patients would be needed 
for the 5% significance level with 80% power. Only patients with at least one matched 
control were accepted for the final study set. For risk factors with 95% confidence interval 
(CI) above one, conditional logistic regression served to examine risk factors independently 
related to Campylobacter infection. 
 
 
4.4.2 Statistical Package for Social Sciences (II-IV) 
 
In studies II-III and IV, statistical analyses were carried out using SPSS Version 11.5 
software (SPSS, IL, USA) and SPSS Version 15.0 software (SPSS, IL, USA), respectively.  
For categorical variables Pearson’s Chi-square, Fisher's Exact, and linear-by-linear tests 
were used, as appropriate. Depending on the distribution, ANOVA or Mann-Whitney’s U 
test was used for continuous variables. For associations Pearson’s correlation coefficients, 
Spearman’s rho, and linear regression were used. Logistic regression was used for 
calculation  of  Odd’s  ratios  (OR)  and  95% Confidence  Intervals  (CI).  Variables  that  were  
significant by univariate analysis were included in the multivariate models. All p-values 
reported were two-sided, with p< 0.05 considered to be statistically significant.  
 
 
 
4.5 Ethical aspects 
 
 
The study was approved by the Ethics Committee of the Hospital District of Helsinki and 
Uusimaa (228/E0/2002). 
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5. RESULTS 
 
 
5.1 Risk factors for Campylobacter infections (I) 
 
Of the 82 exposures analyzed, factors significantly associated with an increased risk for 
Campylobacter infection included: tasting or eating under-cooked or raw meat, 
consumption of strawberries, drinking untreated water from a dug well, and swimming in 
natural sources of water (Table 15).  Food items and other characteristics associated with 
reduced risk of infection are also shown in Table 15. 
 
Table 15. Matched univariate analysis of exposure factors with increased or reduced risk for Campylobacter 
infection  
 
Risk factor Cases 
n = 100 
Controls 
n = 137 
Adjusted 
OR 
95% CI 2-tailed pa 
Increased risk 
Tasting/eating undercooked or 
raw meatc 
Drinking water from a dug well 
Swimming in natural waters 
Eating strawberries 
 
 
14/88 
 
31/96 
48/100 
70/89 
 
3/124 
 
22/137 
40/134 
79/124 
 
 
12.00 
 
3.19 
2.27 
2.90 
 
 
1.54-93.77 
 
1.58-6.45 
1.24-4.16 
1.21-6.95 
 
0.0052b 
 
0.0017 
0.0089 
0.0287 
Reduced risk 
Consumption of: 
  Black and red currants 
  Blueberries  
  Carrots 
  Yoghurt 
  Pasteurized milk 
  Cooked/fried fish 
  Cattle liver 
Drinking water produced by a 
large water plant 
Eating at a friend’s house 
 
 
17/73 
20/73 
43/83 
51/90 
55/93 
50/93 
4/69 
52/97 
 
24/49 
 
 
73/126 
56/118 
89/126 
83/121 
99/131 
98/128 
15/105 
88/137 
 
44/71 
 
 
 
0.17 
0.43 
0.44 
0.35 
0.44 
0.35 
0.18 
0.52 
 
0.35 
 
 
0.07-0.41 
0.21-0.89 
0.24-0.82 
0.15-0.85 
0.22-0.85 
0.18-0.67 
0.04-0.87 
0.26-1.02 
 
0.13-0.96 
 
 
<0.0001 
0.0115 
0.0039 
0.0332 
0.0075 
0.0004 
0.0083 
0.0371 
 
0.0195 
aChi-square test; bFisher’s exact test. 
cOf 14 exposed cases, 13 specified the type of meat. Of these, 8 (57 %) had tasted under-cooked poultry and 5 
(36%) had tasted minced meat. 
 
In the multivariate analysis, three exposure factors showed an independent association with 
Campylobacter infection: tasting or eating undercooked or raw meat, drinking untreated 
water from a dug well, and swimming in natural sources of water. Consuming strawberries 
did not remain an independent risk factor (Table 16). 
 
 
Table 16. Matched multivariate analysis of risk factors for Campylobacter infection  
 
Risk factor   Adjusted OR  95% CI  2-tailed p 
 
Tasting/Eating undercooked meat 10.79    1.31-89.09 0.0272   
Drinking water from a dug well   3.36   1.37-8.24 0.0082 
Swimming in natural waters   2.80   1.23-6.39 0.0145 
Consuming strawberries    1.93   0.67-5.58 0.2255 
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5.2 Bacterial strain and host characteristics of C. jejuni infections (II)  
 
 
5.2.1 General aspects 
 
The patients in the study were slightly older than the general population in the three regions 
(p< 0.0001, t-test); 31% were ? 60 years of age. The gender distribution among the three 
centers was uneven (p= 0.0020, Pearson’s Chi-square), in that there was a higher number of 
females in the Helsinki area (27/39, 69.2%; p= 0.0314, z-test) and of males in the North 
Karelia area (17/22, 77.3%; p= 0.0098, z-test) compared with the general population in 
these two regions.  
 
All but one patient reported diarrhoea (99.1%). Duration of illness is seen in Table 17.  
 
Table 17. Duration of illness 
Duration of illness  No of patients (%) 
Range 
Mean 
2-5 days 
6-10 days 
>10 days 
2-31 days 
8.4 days 
23 (20) 
58 (51) 
26 (23) 
 
 
The duration of illness was not associated with any of the exposure factors, demographical 
characteristics, or the month of stool sample collection. Age was associated with certain 
exposure factors (Table 18). 
 
Table 18. Exposure factors associated with age 
Exposure factor (p*) Age group to which associated 
Regular medication prior to illness** 
(p<0.0001) 
 
Swimming 
(p=0.048) 
 
Consumption of chicken 
(p=0.038) 
 
Eating outside home 
(p=0.0001) 
Less common; 18-39 years 
More common; ? 60 years 
 
More common; 0-5 years 
Less common;  ? 60 years 
 
More common; 18-39 years 
Less common;  ? 60 years 
 
More common; 18-39 years 
Less common;  ? 60 years 
 
*Fisher’s exact test 
**Excluding antimicrobials and acid-reducing medication 
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5.2.2 Antimicrobial treatment and hospitalization 
 
Antimicrobial treatment for C. jejuni infection was given to 86 (86/114, 75.4%) patients; 
macrolides were used most frequently (Table 19) and the treatment duration varied from 
three to 14 days. 
 
Table 19. Antimicrobial treatment (N= 86) for C. jejuni infection 
Antimicrobial treatment 
 
No of patients (% )* 
Macrolides 
  Roxithromycin 
  Erythromycin 
  Azithromycin 
  Clarithromycin 
Fluoroquinolones 
Macrolide+ fluoroquinolone 
Metronidazole 
34 (40) 
21 (24) 
7 (8) 
4 (5) 
2 (2) 
 31 (36) 
6 (7) 
3 (4) 
*Specific antimicrobial unknown for 12 patients 
 
Of the exposure factors, only antimicrobial treatment two weeks prior to becoming ill was 
associated with a less frequent antimicrobial therapy for enteritis (OR= 0.195, CI 0.048- 
0.796, p= 0.023). A total of 54 (47.4%) patients required hospitalization (range 1-8 days, 
mean 3.8 days) because of C. jejuni infection. Characteristics associated with more or less 
common hospitalization are shown in Table 20.  
 
 
Table 20.  Factors associated with hospitalization due to C. jejuni infection by univariate analysis 
 
Association with hospitalization         OR             CI             p 
More common 
  Older age 
  Stool sample collected  in July 
  Eaten strawberries 
 
1.034 
9.9 
2.85 
 
1.013-1.056 
1.17-83.35 
1.143-7.091 
 
0.002* 
0.036* 
0.025** 
Less common 
  Drinking water produced by a 
  large water plant 
 
0.469 
 
0.219-1.001 
 
0.050** 
*by logistic regression 
**by Pearson’s Chi-square 
 
 
Only age remained independently associated with hospitalization (p= 0.0010, OR= 1.040, 
CI 1.016-1.066, logistic regression) in multivariate analysis; when age increased by one 
year, hospitalization was more common by 4.0%. 
 
In univariate analysis, duration of hospitalization was longer among elderly patients (p< 
0.0001, Pearson’s correlation coefficient= 0.369) and those who reported eating 
strawberries in two weeks prior to becoming ill. On the other hand, drinking water 
produced by a large water plant was associated with a shorter hospitalization time (Table 
21). 
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Table 21. Effects of some exposure factors on duration of hospitalization due to C. jejuni infection by 
univariate analysis 
 
Exposure factor associated with: 
 
Mean duration of 
hospitalization (days) 
           
        p* 
Shorter hospitalization time 
  Not eating strawberries 
  Drinking water from a large    
  water plant 
 
3.3 
3.5 
 
0.023 
0.039 
Longer hospitalization time 
  Eating strawberries 
  Not drinking water from a    
  large water plant 
 
3.9 
4.0 
 
0.023 
0.039 
*by Mann-Whitney U-test 
 
 
In multivariate analysis, only age remained independently associated with hospitalization 
time (p<0.0001, Wald’s test) and consumption of strawberries showed a tendency to be 
associated with a longer hospitalization time (p= 0.088, Wald’s test). 
 
 
5.2.3 Serotypes 
 
A total of 12 different serotypes (Table 22) were identified, with three predominant groups: 
Pen 4-complex (23%), Pen 6,7 (21%), and Pen 21 (17%).  
 
Table 22. Geographical distribution and special features of patients infected with certain C. jejuni serotypes 
 
Serotype 
 
Helsinki 
N (%) 
Kuopio 
N (%) 
North Karelia 
N (%) 
Total 
N (%) 
Special features 
Pen 1,44 
Pen 2 
 
Pen 4-complex 
 
Pen 5 
Pen 6,7 
 
 
 
Pen 12 
Pen 15 
Pen 19 
Pen 21 
 
Pen 27 
Pen 55 
Pen 57 
 
 
 
Total 
4 (68) 
0 (0) 
 
14 (54) 
 
1 (50) 
10 (42) 
 
 
 
1 (25) 
0 (0) 
1 (50) 
3 (16) 
 
3 (3) 
1 (20) 
1 (20) 
 
 
 
39 (34) 
1 (17) 
4 (80) 
 
10 (39) 
 
1 (50) 
9 (38) 
 
 
 
3 (75) 
2 (33) 
0 (0) 
14 (73) 
 
3 (30) 
3 (60) 
3 (60) 
 
 
 
53 (47) 
1 (17) 
1 (20) 
 
2 (8) 
 
0 (0) 
5 (21) 
 
 
 
0 (0) 
4 (68) 
1 (50) 
2 (11) 
 
4 (40) 
1 (20) 
1 (20) 
 
 
 
22 (19) 
6 (5) 
5 (4) 
 
26 (23) 
 
2 (2) 
24 (21) 
 
 
 
4 (4) 
6 (5) 
2 (2) 
19 (17) 
 
10 (9) 
5 (4) 
5 (4) 
 
 
 
114 (100) 
 
Younger mean age (25.2 
years, range 15-48 years) 
Swimming infrequent 
(p=0.0406*) 
 
Frequent in July (19/24, 
79.2%, p<0.0001*) 
Recreational use of water  
(p=0.0351*) 
 
 
 
Frequent in August, 12/19, 
63.2% (p= 0.0070*) 
 
 
Older mean age (57.4 years, 
range 33-79 years) 
Shorter disease duration 
(p=0.0052**) 
*Pearson’s Chi-square test 
**Linear-by-linear test 
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As shown in Table 22, recreational use of natural sources of water was associated with 
serotype Pen 6,7. Patients who acquired serotype Pen 4-complex reported swimming less 
frequently  than  expected.  Furthermore,  serotype  Pen  57  was  associated  with  a  shorter  
duration of disease, with 80% (4/5 patients) of the patients reporting a disease duration of 
2-5 days and none >10 days. Serotype was not associated with antimicrobial treatment nor 
hospitalization or its duration. No serotype could be linked to tasting or eating undercooked 
or raw meat or drinking water from a dug well. 
 
 
 
5.3 Antimicrobial susceptibilities of Campylobacter isolates (III) 
 
5.3.1 Domestic isolates 
 
The MICs of the tested antimicrobials for the 393 domestic isolates are shown in Table 23.  
 
Table 23. MICs of five antimicrobial agents for C. jejuni and C. coli isolates of domestic (n= 393) and foreign 
(n=85) origin 
_____________________________________________________________________ 
Antimicrobial  Strain                                        MIC (µg/ml)    
agent            origin*                                                
                                                                                                                                       
____________________________Range  MIC50  MIC90__________ 
 
Erythromycin  D  0.5-8      2  4   
  F  0.5- >1024     4  1024                      
Telithromycin D  0.5-32      2  4 
  F  0.5- >64      4  64 
Ciprofloxacin D  0.06-64      0.125  0.5                                     
  F  0.125- >128     16  64                          
Moxifloxacin D  0.0125-16     0.06  0.125 
  F  0.06-128      4  16 
Doxycycline D  0.06-64      0.125  0.25    
  F  0.06-128      16  64                         
______________________________________________________________________ 
*D, domestic isolate; F, foreign isolate 
 
 
The majority (275/392, 70%) of the isolates inhibited by erythromycin at 0.5-4 µg/ml 
(392/393, 99%) showed MICs of 2µg/ml or less of telithromycin. For telithromycin, 118 
isolates (30%) had MICs > 2 µg/ml. The majority of the domestic isolates (376/393, 95.7%) 
showed low MICs for ciprofloxacin and moxifloxacin (MIC90 values of 0.5µg/ml and 
0.125µg/ml, respectively). Only three isolates (0.8%) had doxycycline MICs ?16 µg/ml and 
these also showed ciprofloxacin MICs ? 8 µg/ml. Another 14 isolates showed ciprofloxacin 
MICs ? 4 µg/ml. 
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5.3.2 Isolates selected by reduced antimicrobial susceptibility 
 
Of the 85 Campylobacter isolates selected on the basis of presumed reduced susceptibility 
to ciprofloxacin and/or erythromycin, 82 isolates (78 patients having a history of travelling 
abroad) had MICs ?4 µg/ml for ciprofloxacin (Table 24). Of all the isolates with reduced 
susceptibility to ciprofloxacin (n=99), 91 (92%) had moxifloxacin MICs > 2 µg/ml and 53 
(54%) had doxycyline MICs ? 16 µg/ml.  
 
Table 24. Distribution of doxycycline, erythromycin, and telithromycin MICs for Campylobacter isolates with 
ciprofloxacin MICs of ?4 ?g/ml. 
_________________________________________________________________________________ 
             No. of isolatesa 
 
MIC (?g/ml)         Doxycycline            Erythromycin  Telithromycin_____ 
 
  Domestic         Foreign       Domestic  Foreign           Domestic      Foreign 
0.060  0  1     NT     NT  0  0 
0.125  9  19b      0       0  0  0 
0.25  2  7      0       0  0  0 
0.5  0  1      0       2  1  5 
1  0  2b         6       13b  1  6 
2  1  0      6      25  5  20b 
4  1  1      5     18b  9  20 
8  1  1      0       7  1  10b 
16  2  18b         0        0  0  3 
32  0  12      0       0  0  3 
64  1  17b      0       0  0  14d 
128*  0  3      0       0  0  1 
256  NT  NT      0       1  NT  NT 
512  NT  NT      0       1  NT  NT 
1024  NT  NT      0       7  NT  NT 
>1024  NT  NT      0       8c  NT  NT 
NT, not tested 
a17 strains of domestic origin, 78 strains of foreign origin, and 4 strains from patients with unknown travelling 
history 
bone strain with unknown travelling history 
ctwo strains with unknown travelling history 
done strain with unknown travelling history and one strain with no travelling history 
*for telithromycin MIC > 64 ?g/ml 
  
Twenty-five isolates (one domestic, 22 of foreign origin, two from patients with unknown 
travel history) showed reduced susceptibility to erythromycin (MICs > 8 µg/ml).  Of these 
25 isolates, nine were C. jejuni and 16 C. coli; telithromycin MICs for these isolates ranged 
from 4- 64 µg/ml and 4- >64 µg/ml, respectively (Table 25).  
 
Table 25. Distribution of telithromycin MICs for 25 isolates with erythromycin MICs ???g/ml 
 
Erythromycin MIC (?g/ml) 
(No of isolates) 
Telithromycin MIC range 
??g/ml) 
Doxycycline MIC range 
??g/ml) 
 
8 (8) 
256 (1) 
512 (1) 
1024 (7) 
>1024 (8) 
4-64  
4 
4  
16- >64  
32-64  
0.5- >64  
16  
16  
16- >64  
16- >64  
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Of these 25 isolates, 23 also showed doxycycline MICs ?16 µg/ml. Fifteen isolates (11 C. 
coli and  4 C. jejuni) showed very high erythromycin MICs (?1024 µg/ml); 13 (87%) of 
foreign origin and two from patients with unknown travel history. Twenty-three isolates (21 
of foreign origin and two from patients with unknown travel history) showed 
simultaneously reduced susceptibility to ciprofloxacin (MICs ? 4 µg/ml), erythromycin 
(MICs ? 8 ug/ml) and doxycycline (MICs ?16 µg/ml), and the MIC range of telithromycin 
was 4- >64 µg/ml.  
 
 
5.3.3 Disk diffusion 
 
The correlation between MICs of erythromycin and ciprofloxacin in the agar dilution 
method as compared to the zone diameters in the disk diffusion tests is shown in Table 26. 
Ninety-six isolates had no inhibition zones in the disk diffusion test for ciprofloxacin; the 
ciprofloxacin MICs in these particular cases were all > 8 µg/ml.  
 
Table 26. Correlation between MICs of erythromycin and ciprofloxacin as compared to the zone diameters in 
the disk diffusion method 
 
MICs (?g/ml) 
 
Zone diameter range  
              (mm) 
Number of isolates 
         (n= 478) 
Erythromycin 
0.5 
1 
2 
4 
8 
16 
32 
64 
128 
256 
512 
1024 
>1024 
 
Ciprofloxacin 
0.060 
0.125 
0.25 
0.5 
1 
2 
4 
8 
16 
32 
64 
128 
>128 
                                       
34-42                                   
27-50                                    
27-42 
25-40 
16-28 
ND 
ND 
ND 
ND 
6 
6 
6 
6 
 
                              
42-50 
30-57 
32-50 
33-50 
30-40 
30 
41 
6-15 
6 
6 
6 
6 
6 
 
5 
129 
250 
69 
8 
0 
0 
0 
0 
1 
1 
7 
8 
 
                                        
8 
210 
125 
33 
2 
1 
1 
14 
40 
19 
17 
7 
1 
ND, not done; 6mm, no zone of inhibition 
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5.4 Complications after C. jejuni  infections (IV) 
 
5.4.1 General aspects 
 
Demographical characteristics and symptoms of the 201 patients included in the study are 
seen in Table 27. Bloody diarrhoea was more common than expected in the younger age 
groups, 0-5 years and 6-17 years, (p=0.001, Fisher’s exact test).  
 
Table 27. Demographical characteristics and symptoms of patients with domestically-acquired C. jejuni 
infection 
 
Feature Outpatients 
(n= 121) 
Hospitalized patientsa 
(n= 80) 
All patients (n= 201) 
(%) 
Demographics 
  Median age (years) 
  Gender (females/males) 
  Urban/rural residence 
Symptoms 
 Diarrhoea 
  Median duration of diarrhoea (days) 
  Bloody diarrhoea 
  Nausea 
  Fever >39°C                                            
  Stomach ache 
  Vomiting 
  Headache 
 
42 
55/66 
59/62 
 
121 
7  
15 
43 
96  
90 
7 
3 
 
57 (p<0.001) b 
42/38 
42/38 
 
80 
5 (p=0.04) c 
7 
39 
75 (p=0.002) d 
61 
15 
7 
 
50 (range 1-88 years) 
97 (48)/104 (52) 
101/100 
 
201 (100) 
6 (range 1 to > 30 days) 
22 (11) 
82 (41) 
171 (85) 
151 (75) 
22 (11) 
10 (5) 
amedian hospitalization time was 4.0 days (range 1-20 days) 
blinear regression; cMann-Whitney U-test; dChi-square test 
 
 
A  patient  was  classified  to  have  ReA  on  the  basis  of  information  from  medical  records.  
Achilles enthesopathy and/or heel pain and other extra-articular symptoms associated with 
C. jejuni enteritis, were recorded on the basis of information included on the questionnaire. 
Other self-reported joint symptoms connected to C. jejuni enteritis, excluding previously 
known joint diseases, were recorded as Campylobacter-associated joint symptoms. 
Synovitis was defined as simultaneous joint pain with movement restriction and/or joint 
swelling recorded on the basis of information on the questionnaire. 
 
 
5.4.2 Musculoskeletal complications 
 
In total, 79 (79/199, 39%) patients reported musculoskeletal symptoms associated with C. 
jejuni enteritis (Table 28). The most commonly reported symptoms were joint pain (64/72, 
81%) and lower back pain (42/74, 53%). Patients reported symptoms suggestive of 
synovitis (31/74, 42%) in joints of both upper (shoulder, elbow, wrist, hands, and fingers) 
and lower (hip, knee, ankle, foot, and toes) limbs. Stomach ache during enteritis was 
associated with later development of joint pain (p=0.027, Chi-square test). 
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Table 28. Patients (n=79) reporting musculoskeletal symptoms in association with C. jejuni enteritis 
 
Features 
 
Number of patients* 
          (%) 
Gender 
  Female 
  Male 
Median age (years) 
Age groups 
  0-5 years 
  6-17 years 
  18-39 years 
  40-59 years 
  ? 60 years 
Number of affected joints 
  1 joint 
  2-5 joints 
  > 5 joints 
Joint symptoms 
  Joint pain 
  Restricted movement 
  Swelling and/or warmth   
  Symptoms suggestive of synovitis** 
  Lumbar pain 
  Neck pain 
Duration between start of diarrhoea and 
musculoskeletal symptoms 
  0-6 days 
  7-30 days 
  > 30 days 
  before start of diarrhoea 
  median duration (days) 
Duration of musculoskeletal symptoms 
  2-7 days 
  8-14 days 
  15-30 days 
  >30 days 
Contacted physician 
  Reported joint pain 
  Reported joint swelling 
  Symptom duration > 30 days 
 
43/79 (54) 
36/79 (46) 
51 (range 3-88) 
 
2/71 (3) 
3/71 (4) 
16/79 (20) 
32/79 (41) 
26/79 (33) 
 
3/46 (7) 
12/46 (26) 
31/46 (67) 
 
64/72 (89) 
27/72 (38) 
24/71 (34) 
31/74 (42) 
42/74 (57) 
30/73 (41) 
 
 
17/42 (40) 
13/42 (31) 
8/42 (19) 
4/42 (10) 
7 (range 0-60 days) 
 
14/48 (29) 
6/48 (13) 
5/48 (10) 
23/48 (48) 
10/78 (13) 
9/10 
6/10 
5/7 
*Number of positive responses out of all responses to the variable in question  
**Joint pain with swelling and/or movement restriction 
 
 
 
Only lower back pain was associated with gender; it was more common than expected 
among females (p= 0.013, Chi-square test). Musculoskeletal symptoms showed an increase 
in incidence of 1.4% per year of age (p= 0.045, OR= 1.0, CI= 1.0-1.1, logistic regression, 
Wald’s test); the associated symptoms were movement restriction of the joint, joint 
swelling/warmth, symptoms suggestive of synovitis, lower back pain, and heel pain. 
 
Symptoms were most commonly reported from large joints (55/79, 69.6%), followed by 
symptoms from the lower back and/or neck (53/79, 67.1%), and small joints (33/79, 
41.8%).  Small joints were more commonly affected among females (p= 0.004, Chi-square 
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test) and females also reported symptoms from >5 joints more often than males (p= 0.007, 
Fisher's exact test).  
 
Four  patients  were  diagnosed  with  ReA by  a  physician  and  according  to  medical  records  
another four had clinical evidence of suspected ReA (Table 29). The most frequently 
affected joints were ankles (6 patients) and knees (4 patients). The onset of symptoms 
varied between 6 to 60 days after the onset of diarrhoea (one patient reported the arthritis to 
have started three days before the diarrhoea). The duration of the diagnosed/suspected ReA 
ranged from four days (1 patient) up to >30 days (6 patients). The median duration of 
diagnosed/suspected ReA together with Achilles enthesopathy and/or heel pain, was 
significantly longer (31 days) than that of other Campylobacter-associated joint symptoms 
(10 days), (p<0.014, Mann-Whitney U-test).  
 
 
Table 29. Patients with diagnosed or suspected ReA; demographics and symptoms 
 
Feature 
 
Number of patients 
(n= 8) 
Gender 
  Females/Males 
Age groups 
  18-39 years 
  40-59 years 
  ? 60 years 
Number of affected joints 
  1 joint 
  2-5 joints 
  > 5 joints 
Joint symptoms 
  Joint pain 
  Movement restriction 
  Swelling and/or warmth 
  Symptoms suggestive of  synovitis 
  Neck pain 
  Lumbar pain 
Contacted physician 
  Hospitalized 
 
4/4 
 
2 
4 
2                                    
 
1 
3 
4 
 
8 
6 
6 
7 
3 
2 
8 
2 
 
Eighteen (9%) patients (age range 3 to 80 years) had Achilles enthesopathy and/or heel pain 
(two children: 3 years and 15 years of age), but only one patient visited a physician. Other 
simultaneous reactive symptoms are seen in Table 30. 
 
 
 
Table 30. Reactive symptoms simultaneously with Achilles enthesopathy and/or heel pain 
 
Reactive symptom 
 
No of patients  
         (%) 
Eye symptoms  (pain, redness, sensitivity to light, discharge) 
Urinary symptoms (discharge, dysuria) 
Eye and urinary symptoms 
Eye symptoms and symptoms suggestive of synovitis 
Urinary symptoms and symptoms suggestive of synovitis 
8 (5) 
2 (1) 
1 (0.5) 
4 (2) 
3 (2) 
 52 
Simultaneous symptoms suggestive of synovitis, reactive eye, and/or urinary symptoms in 
seven patients (Table 30), indicated possible Reiter’s syndrome or incomplete Reiter (no 
urethritis). Development of ReA or Achilles enthesopathy and/or heel pain was not 
associated with the severity of enteritis or the use of antimicrobial treatment for enteritis.   
 
 
5.4.3 Intestinal complications 
 
According to the questionnaire, one patient was diagnosed with active colitis and one 
patient, as based on medical records, presented with symptoms suggesting post-infectious 
irritable bowel syndrome (IBS) with persisting diarrhoea one year after infection.  
 
 
5.4.4 Serotypes 
 
Fifteen different serotypes were identified. Findings related to certain serotypes are seen in 
Table 31.  
 
Table 31. Findings related to certain C. jejuni serotypes 
 
Serotype Penner Finding 
 
4-complex 
6,7 
21 
2 
 
most common, n= 38 (19%); 61% from an urban area  
very common n= 35 (17%) 
common n= 23 (11%);  70% from a rural area  
n= 13 (7%); associated with bloody diarrhoea (p= 0.0018*) and 
young age (p< 0.0001)* 
*Fisher’s exact test 
 
In multivariate analysis, serotype Pen 2 (p=0.005, OR=17.4, CI=2.3-129.2, Wald's test, 
logistic regression) and the age group 0-5 years (p= 0.004, OR=17.1, CI=2.5-118.9, Wald's 
test, logistic regression) remained independent significant risk factors for bloody diarrhoea.  
 
 
5.4.5 Antimicrobial treatment 
 
In total, 148 (74%) patients received antimicrobial treatment for C. jejuni infection. 
Appropriate antimicrobial treatment, as based on MICs in susceptibility testing  by the agar 
dilution method, for enteritis did not affect the duration of diarrhoea or the incidence of 
complications. However, if appropriate antimicrobial treatment was initiated within two 
days of the start of the diarrhoea, the median duration of the diarrhoea was shortened by 2.5 
days (p= 0.009, Mann-Whitney U-test) (Table 32). Hospital patients were treated more 
often with antimicrobials as compared to those visiting an outpatient clinic (p= 0.0046, Chi-
square test) (Table 32). Antimicrobial treatment was also more common in the more urban 
areas as compared to the more rural ones (p= 0.038, Fisher’s exact test) (Table 32). 
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Table 32. Features of antimicrobial treatment for C. jejuni enteritis 
 
Antimicrobial treatment 
 
No of patients (%); special feature 
 
Appropriate treatmenta 
   Median delay of treatment initiationb 
  Treatment initiated within 2 days 
  Treatment initiated ? 3 days 
Urban/rural area 
Median duration 
Antimicrobial agent 
  Fluoroquinolones 
  Macrolides 
  Fluoroquinolone+macrolide 
Treated at hospital/outpatient clinic 
124 (84) 
4 days (range 0-61 days) 
15 (26); median duration of diarrhoea 4.5 days, p= 0.009c 
43 (74); median duration of diarrhoea 7 days, p= 0.009c 
81/67; p=0.038d 
7 days (range 2-10 days) 
 
54 (37) 
52 (35) 
5 (3) 
65 (44)/83 (56); p=0.046 e 
aas interpreted on the results of antimicrobial susceptibility testing (III) 
binformation available only for three centers included in study (I) 
cMann-Whitney U-test; dFisher’s exact test; eChi-square test 
 
 
Fluoroquinolones were used more often in hospitalized patients (p<0.0001, Chi-square test) 
and macrolides for patients in the primary health care (p=0.016, Chi-square test).  
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6. DISCUSSION 
 
 
6.1 Risk factors for Campylobacter infections (I) 
 
This study identified three independent risk factors for domestically-acquired 
Campylobacter infection: tasting or eating raw or under-cooked meat, drinking water from 
a dug well, and swimming in natural water.  These risk factors accounted for 67% of the 
infected cases.  
 
Consuming undercooked or raw meat was an independent risk factor, supporting previous 
studies identifying consumption of under-cooked poultry as a risk factor (Ikram et al., 
1994; Eberhart-Phillips et al., 1997; Neimann et al., 2003).  Consumption of poultry, 
however, was not a risk factor as such, in contrast to some previous studies (Kapperud et 
al., 1992; Shorr et al., 1994; Eberhart-Phillips et al., 1997; Studahl & Andersson, 2000). In 
Finland, poultry is mostly sold in pre-packed ready-to-use consumer packages requiring 
minimal handling in the kitchen; thus, cross-contamination may be largely prevented. 
Previously, Kapperud (Kapperud et al., 2003) showed that eating chicken as such was not a 
significant risk for acquiring Campylobacter infection, but chicken products bought raw 
elevated the risk, thus suggesting the importance of cross-contamination. 
 
Private water supplies presented a significant risk factor for sporadic Campylobacter 
infection; previously, drinking untreated water has been identified as a risk for sporadic 
Campylobacter infection (Adak et al., 1995; Kapperud et al., 2003; Friedman et al., 2004) 
and a study from England and Wales found Campylobacter responsible for most outbreaks 
associated with private water supplies in 1992 to 1995 (Furtado et al., 1998). In Finland, 
private wells are used in about 310 000 households and approximately 300 000 summer 
cottages (Korkka-Niemi & Sipilä, 1993; Etelämäki, 1999). Dug wells are susceptible to 
surface water contamination (Korkka-Niemi, 2001) and the summer of 2002 was 
exceptionally dry, resulting in poor water quality in these wells due to low ground-water 
levels. 
 
In  contrast,  consumption  of  water  from  a  large  water  plant  seemed  to  protect  against  
Campylobacter infection; large water plants distribute surface water after multi-stage 
purification and disinfection procedures (Miettinen et al., 2001). Most of the 33 waterborne 
outbreaks in Finland during 1998 to 2002 (Vartiainen et al., 2003) were associated with 
water plants distributing nondisinfected groundwater.  
 
Swimming in natural sources of water was identified as a novel independent risk factor for 
Campylobacter infection. As the infective dose for Campylobacter infection is low 
(Robinson, 1981; Black et al., 1988), contaminated surface water may pose a risk for 
acquiring the infection through swimming, since Campylobacter is commonly found in 
natural waters (Jones, 2001; Hörman et al., 2004). Previously, drinking untreated water 
(from a lake, river, or stream) was identified as a risk factor for Campylobacter infection 
(Friedman et al., 2004). 
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Eating strawberries did not remain an independent risk factor in multivariate analysis. 
Interestingly,  outside  the  study  region,  a  small  outbreak  was  reported  for  which  the  
suspected source was eating strawberries directly from the field (Hatakka et al., 2003).  
 
Reduced risk for infection was associated with eating berries and carrots, consistent with 
some previous results (Eberhart-Phillips et al., 1997; Kapperud et al., 2003; Neimann et al., 
2003; Stafford et al., 2007; Gallay et al., 2008); this could indicate a healthy lifestyle, 
which may be protective against gastrointestinal illness. Consumption of yoghurt, 
pasteurized milk, and cooked fish may be related to the same phenomenon.  
 
Eating outside the home and contact with farm or pet animals did not pose an increased risk 
for Campylobacter infection, opposite to some previous findings (Skirrow, 1982; Eberhart-
Phillips et al., 1997; Tenkate & Stafford, 2001; Neimann et al., 2003; Gallay et al., 2008). 
These contradictory findings imply that the relative importance of risk factors for sporadic 
Campylobacter infections may vary between countries.  
 
 
 
6.2 Role of bacterial strain and host characteristics in C. jejuni infections (II)  
 
The relative importance of identified risk factors for Campylobacter infection in sporadic 
cases is not known. Several sources of infection exist but their role may vary in different 
patient groups. This study suggests that C. jejuni may be acquired from different sources in 
individuals from different geographical areas and age groups. The distribution of exposure 
factors and C. jejuni serotypes between the different groups of individuals supports this 
hypothesis. 
 
The role of swimming as a significant risk factor for Campylobacter infection may be 
especially important for very young patients; swimming was significantly more common 
among  children  aged  ? 5  years  than  in  older  age  groups  and  swimmers  tend  to  swallow  
small volumes of water (Pruss, 1998; Shuval, 2003).  In contrast,  individuals of age ? 60 
years reported swimming less often, suggesting that other risk factors for Campylobacter 
infection may be more relevant in this patient group. The relative importance of different 
risk factors in different age groups was further supported by the finding that consumption 
of chicken and eating food that has not been prepared in the home, earlier demonstrated risk 
factors, were significantly more common in patients aged 18-39 years as compared to age ? 
60 years.  
 
A high proportion of patients (47%) were hospitalized because of Campylobacter infection. 
A  recent  Finnish  study  and  some  other  reports  have  shown  lower  hospitalization  rates  
(Samuel et al., 2004; Feodoroff et al., 2009). The age distribution of the patients in the 
present study may explain the high hospitalization rate to some extent; 31% of the patients 
were ? 60 years of age. Campylobacter infection shows two age peaks in general; children 
<4 years of age and young adults aged 15 to 44 years (Blaser, 1997; Samuel et al., 2004). 
The high number of elderly Campylobacter patients may be typical for Finland (Vierikko et 
al., 2004). Increasing age in our study was associated with hospitalization, also shown 
 56 
previously (Samuel et al., 2004), and with longer time spent at hospital. No specific risk 
factors, however, were associated with old age, hampering the focus of preventive measures 
among this age group.  
 
The unequal gender distribution in North Karelia with a majority of male patients and in 
Helsinki with a majority of female patients is difficult to explain. In general, there is a male 
predominance among Campylobacter patients (Skirrow, 1987; Amato-Gauci & Ammon, 
2007; Gillespie et al., 2008). Altekruse and colleagues (Altekruse et al., 1996) reported of 
more unsafe food-handling, preparation, and consumption practices among males. Samuel 
and colleagues (Samuel et al., 2000) reported of men eating more foods known to be risky 
for foodborne diseases, including Campylobacter. Occupational and behavioural 
differences which may exist between males and females not covered by our investigation 
could in part explain the gender differences.  
 
Antimicrobial  treatment  was  common  (75%),  also  shown  in  another  Finnish  study  by  
Feodoroff and colleagues (Feodoroff et al., 2009). The common use of antimicrobial 
therapy could in part be explained by the study design; only patients with a positive stool 
sample for Campylobacter were included possibly leaving out enteritis patients with a 
milder  form  of  enteritis  where  a  stool  sample  did  not  seem  necessary.  A  microbiological  
diagnosis may also favour antimicrobial therapy over symptomatic treatment. Macrolides 
were most frequently used and are the drugs of choice. In Finland, resistance to 
fluoroquinolones has remained low in domestically-acquired cases (Rautelin et al., 2003), 
and can be used as an alternative to macrolides.  
 
The three most common serotypes, Pen 4-complex, Pen 6,7, and Pen 21, accounted for 61% 
of the cases. In a previous Finnish study, serotypes Pen 4-complex and Pen 6,7 were also 
among the  three  most  common ones,  whereas  Pen  12  instead  of  Pen  21,  belonged  to  the  
predominant groups (Vierikko et al., 2004). Some predominant serotypes and genotypes 
seem to encompass most of the domestically-acquired infections, although their relative 
importance may vary from year to year (Hänninen et al., 2000; Kärenlampi et al., 2003).  
 
The geographical distribution of Campylobacter serotypes  has  been  shown  to  vary  
(Vierikko et al., 2004); in the present study the Pen 4-complex accumulated in the urban 
Helsinki area, whereas Pen 21 in the rural Kuopio area. This may suggest different sources 
of infection in different geographic areas. The temporal distribution of the serotypes also 
varied; serotype Pen 6,7 was common in July, also shown previously (Vierikko et al., 
2004), whereas Pen 21 was significantly more frequent in August. This implies a temporary 
fluctuation in C. jejuni types in the environment and human infections. 
 
Swimming in natural sources of water was associated with serotype Pen 6,7, which was 
frequent in July, when swimming is most popular (holiday season). Serotype Pen 6,7 seems 
to be widely distributed in the environment, as it has previously been found in July both in 
chicken (Perko-Mäkelä et al., 2002) and human infections (Vierikko et al., 2004).   
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6.3 Antimicrobial susceptibilities of Campylobacter to telithromycin, erythromycin, 
fluoroquinolones, and doxycycline (III) 
 
The susceptibility of both foreign and domestic Campylobacter isolates to erythromycin 
has remained high in Finland; only one isolate (n=393) of domestic origin had an 
erythromycin  MIC  >  4µg/ml.  Even  among  isolates  selected  on  the  basis  of  presumed  
reduced susceptibility, only a few isolates showed elevated erythromycin MICs; earlier 
studies have also shown a stable macrolide activity against Campylobacter (Rautelin et al., 
1991; Engberg et  al., 2001; Rautelin et al., 2003; Engberg et al., 2004). Reduced 
susceptibility to erythromycin was more prevalent among C. coli than C. jejuni isolates, 
also shown previously (Sánchez et al., 1994; Aarestrup et al., 1997; Engberg et al., 2001; 
Engberg et al., 2004). In addition, the majority of isolates with very high erythromycin 
MICs were C. coli, as observed previously (Li et al., 1998). 
 
Telithromycin did not have an advantage over erythromycin against Campylobacter 
isolates. Accordingly, Hakanen and colleagues (Hakanen et al., 2003b) demonstrated 
elevated telithromycin MICs for some Campylobacter isolates with reduced susceptibility 
to erythromycin and one quite recent study showed that telithromycin had low activity 
against Gram-negative non-respiratory pathogens including Campylobacter (Felmingham 
& Farrell, 2006). 
 
Among Campylobacter, resistance to fluoroquinolones has been frequently observed during 
the past 15 years (Endtz et al., 1991a; Rautelin et al., 1991, Engberg et  al., 2001); this 
phenomenon has been linked to travel and the use of fluoroquinolones in veterinary 
medicine (Endtz et al., 1991a; Smith et al., 1999; Hakanen et al., 2003a; Engberg et  al., 
2004). In the present study, reduced susceptibility to fluoroquinolones was almost 
exclusively detected among isolates of foreign origin and half of these isolates also showed 
high doxycycline MICs. However, susceptibility to fluoroquinolones among domestic 
Campylobacter isolates has remained consistently high (Rautelin et al., 2003) as confirmed 
in this study. Similar results of low fluoroquinolone resistance rates among domestic 
Campylobacter isolates have been reported in Australia and Sweden (Sjögren et al., 1997; 
Unicomb et al., 2003) and this may in part be explained by the lack of fluoroquinolone use 
in food production animals (Unicomb et al., 2003, FINNRES-Vet, 2004).  
 
Doxycycline showed a high activity against domestic Campylobacter isolates, in contrast to 
some other studies (Sjögren et al., 1997; Smith et al., 1999). Among the isolates with 
reduced susceptibility to ciprofloxacin, 54% were inhibited only by high concentrations of 
doxycycline. Others report of reduced susceptibility to both ciprofloxacin and a tetracycline 
agent and which varied between 25-50% (Gomez-Garces et al., 1995; Sjögren et al., 1997). 
Reduced susceptibility to several antimicrobials was also seen in our study; 92% of the 
isolates with reduced susceptibility to ciprofloxacin showed high MICs for moxifloxacin 
and 25% had erythromycin MICs ? 8 µg/ml. Furthermore, of the isolates with reduced 
susceptibility to both ciprofloxacin and doxycycline (n=53), 43% had erythromycin MICs 
?8 ug/ml. In other reports, fluoroquinolone-macrolide co-resistance has varied from 0.2% 
to 15% (Sjögren et al., 1997; Hoge et al., 1998; Engberg et al., 2004). In a Finnish study 
(Hakanen et al., 2003b), 22% of Campylobacter strains isolated from travellers were 
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detected to be multiresistant. Telithromycin does not offer an advantage for multiresistant 
strains; for the 23 isolates in our study with reduced susceptibility to ciprofloxacin, 
doxycycline, and erythromycin, all showed telithromycin MICs > 2 µg/ml. In cases of 
multiresistant Campylobacter infection, antimicrobial therapy when needed may be 
challenging.   
 
In clinical microbiology laboratories, an agar dilution method used in the present study is 
not  practical  for  routine  use.  Therefore,  we  compared  the  MICs  of  erythromycin  and  
ciprofloxacin obtained in the agar dilution method with the zone diameters in a disk 
diffusion test and the correlation was good, also later shown by Gaudreau and colleagues 
(Gaudreau et al., 2007). All the isolates in this study with no inhibition zone for 
ciprofloxacin showed ciprofloxacin MICs ?8 µg/ml. Also, most isolates with erythromycin 
MICs ? 8µg/ml showed no inhibition zones in the disk diffusion test. In 2006, the CLSI 
approved of a disk diffusion method for erythromycin and ciprofloxacin for Campylobacter 
jejuni/coli (CLSI, 2006). 
 
 
6.4 Complications after C. jejuni infections (IV) 
 
Musculoskeletal symptoms in connection to C. jejuni enteritis were commonly reported 
(39%). Campylobacter as a trigger of ReA is increasingly important (Söderlin et al., 2003; 
Leirisalo-Repo, 2005; Townes et al., 2008). The incidence of classical ReA in this study 
was moderate (4%), in concordance with some previous reports (Hannu et al., 2002; Pope 
et al., 2007; Shiellerup et al., 2008). However, of all the 79 patients reporting any 
musculoskeletal symptoms connected to the enteritis, 67% had reactive Campylobacter-
associated joint symptoms other than ReA, Achilles enthesopathy and/or heel pain. These 
particular Campylobacter-associated joint symptoms were of milder character. In  this  
study, females, shown to have a higher risk for ReA (Townes et al., 2008), reported more 
often than males polyarthralgia of the small joints of the hands and feet. Originally, when 
Ahvonen and colleagues described Yersinia-triggered ReA in 1969 (Ahvonen et al., 1969), 
they  reported  involvement  of  the  small  joints  of  the  hands  and  feet.  This  has  later  been  
shown also after Campylobacter infection (Kosunen et al., 1981; Hannu et al., 2002).  
 
Only 13% of patients with musculoskeletal symptoms visited a physician and of those 71% 
reported duration of symptoms to be > 30 days. As previously reported, enthesopathy 
seldom leads to health care contact (Hannu et al., 2002). In this study Achilles 
enthesopathy and/or heel pain was reported by 9% of the patients but only one patient 
visited a physician.  
 
Hannu and colleagues reported stomach ache of longer duration to be associated with 
reactive musculoskeletal symptoms, including joint pain (Hannu et al., 2002). Development 
of joint pain in our study was associated with stomach ache during enteritis. There was not, 
however, an association between other characteristics of serious enteritis and ReA, Achilles 
enthesopathy and/or heel pain, or other Campylobacter-associated musculoskeletal 
symptoms, in contrast to some previous studies (Hannu et al., 2002; Locht & Krogfelt, 
2002; Schiellerup et al., 2008). Furthermore, antimicrobial treatment did not prevent 
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reactive joint symptoms, also reported previously (Locht & Krogfelt, 2002; Townes et al., 
2008). 
 
The response rate was 64% (after excluding one centre). The patient series was 
representative with respect to gender, age, and seasonal distribution. However, our material 
may be biased in that persons with milder enteritis might not have visited a physician at all 
and thus, this patient cohort might over-represent those with more severe enteritis or other 
sequelae due to C. jejuni infection. Being a study based on microbiological diagnosis of C. 
jejuni infection, this study did not include patients with musculoskeletal symptoms due to 
undiagnosed Campylobacter enteritis. Also data relying on the patient’s own observations 
should be interpreted with caution. Patients who have experienced enteritis may be more 
observant for other symptoms as well, thus over-reporting joint symptoms and other 
complications. Medical reports, available in our study for a moderate number of patients, 
were of help, but could not replace the clinical assessment of the patient.  
 
It has been difficult to link specific C. jejuni serotypes to the severity of diarrhoeal illness. 
In this study, serotype Pen 2 was independently associated with bloody diarrhoea and very 
young age (0-5 years). Young age has previously been associated with bloody 
Campylobacter diarrhoea (Gillespie et al., 2006, Gallay et al., 2008). Intestinal 
complications associated with Campylobacter diarrhoea include inflammatory bowel 
disease (García Rodríguez et al., 2006; Ternhag et al., 2008) and post-infectious IBS 
(Smith & Bayles, 2007). This study identified one patient with diagnosed active colitis and 
another patient presented with symptoms suggestive of post-infectious IBS. Due to the 
short follow-up period in this study, the incidence of long-term intestinal complications was 
probably underestimated.  
 
In concordance with some previous results (Townes et al., 2008; Feodoroff et al., 2009), 
antimicrobial treatment for Campylobacter enteritis was very common (73%). 
Fluoroquinolones were commonly used among hospitalized patients and macrolides in the 
outpatients. Antimicrobial treatment initiated within two days of the start of diarrhoea 
shortened the median duration of diarrhoea by two days, a finding supported by a recent 
meta-analysis (Ternhag et al., 2007). Campylobacter enteritis is usually a self-limiting 
disease. Antimicrobial therapy should be used restrictively, as supported by the results from 
this study since antimicrobials did not prevent complications and seemed to have only 
marginal effect on diarrhoea. 
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7. SUMMARY 
 
 
In addition to the known risk factor of consuming raw or undercooked meat, this study 
could clearly identify water as an important risk for domestically-acquired Campylobacter 
infections. The novel finding that swimming in natural sources of water was associated 
with increased risk for infection further emphasizes the importance of other water-related 
exposure factors.   
 
There may be different sources of infection for C. jejuni infection in different geographical 
areas and age groups. This is supported by the variety of exposure factors, such as 
swimming, and C. jejuni serotypes in different patient groups.  
 
Erythromycin consistently shows high activity in Finland against Campylobacter isolates of 
both domestic and foreign origin. Telithromycin does not have any advantage over 
erythromycin; high telithromycin MICs have been demonstrated for isolates with reduced 
susceptibility to erythromycin. Isolates with decreased susceptibility to fluoroquinolones 
often show reduced susceptibility to other antimicrobials, such as doxycycline. In clinical 
laboratories, the disk diffusion method could be used to detect Campylobacter isolates with 
reduced susceptibility to ciprofloxacin and erythromycin.   
 
Musculoskeletal symptoms connected to C. jejuni enteritis of domestic origin are common 
(39%), with joint pain being the most frequent. In addition to diagnosed classical ReA 
occurring in about 4% of the cases, other Campylobacter-associated reactive joint 
symptoms are common; due to their milder nature, however, patients seldom visit a 
physician and thus, these symptoms remain undiagnosed. Although stomach ache during 
enteritis may predict further development of later joint pain, the underlying mechanisms 
behind the frequently occurring musculoskeletal complications associated with 
Campylobacter infection remain to be studied.  
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8.  CONCLUSIONS 
 
 
1. Swimming in natural waters was a novel risk factor for Campylobacter infection. In 
addition, drinking untreated water from a dug well and consuming raw or 
undercooked meat were independent risk factors for domestically-acquired 
Campylobacter infections in Finland (I). 
 
 
2. Some C. jejuni serotypes and exposure factors were more common in certain age 
groups, and some serotypes accumulated in certain months and geographical areas. 
Swimming was associated with serotype Pen 6,7 and may be an especially 
important risk factor for very young patients (II). 
 
 
3. The in vitro antimicrobial susceptibility of Campylobacter for erythtromycin was 
good among both domestic and foreign isolates; telithromycin did not offer any 
advantage over erythromycin. Fluoroquinolone-resistance, often together with 
doxycycline-resistance, was almost exclusively found in foreign isolates. Results 
from the agar dilution and disk diffusion methods correlated well (III). 
 
 
4. Musculoskeletal symptoms connected with C. jejuni enteritis were commonly 
reported (39%); joint pain was the most frequent symptom. In addition to classical 
ReA occurring in approximately 4% of patients, other Campylobacter-associated 
reactive joint symptoms were common, but due to their milder nature, seldom seen 
and diagnosed by a physician. No association was found between musculoskeletal 
complications and the serotype or antimicrobial treatment for enteritis (IV). 
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